Kallu personal page - To The Moon

Kallu

Kallu

To achieve your own goals, start by helping others achieve theirs. Study and steady wins the race.

47Follow

22Followers

1Topic

0Badge

2024-12-17

$Tonix Pharmaceuticals(TNXP)$ 5$ soon @Barcode @TigerGPT @Tiger_SG

2024-12-16

$Tonix Pharmaceuticals(TNXP)$ go go @TigerGPT $Tonix Pharmaceuticals(TNXP)$

2024-10-30

$Trump Media & Technology(DJT)$ it's glitch.. 60$ is loading.. @@Barcode you're strong analysis required here to save me 😭😭😭$Trump Media & Technology(DJT)$

2024-10-15

"Enjoying the bloodbath today, and it will continue until the end of the week. Prepared for everything."$NVIDIA Corp(NVDA)$ $Aspen Aerogels(ASPN)$ $Tiger Brokers(TIGR)$$NASDAQ 100(NDX)$ $.SPX(.SPX)$ @Barcode @TigerGPT Why!!!

2024-11-20

$Tonix Pharmaceuticals(TNXP)$

$Tonix Pharmaceuticals(TNXP)$

@Barcode @TigerGPT $Tonix Pharmaceuticals(TNXP)$

2024-10-08

$Vincera Pharma, Inc.(VINC)$ buy soon before the blast

Vincerx Pharma Reports 'Positive' Initial Clinical Data on Leukemia Drug; Shares Jump After Hours

2024-10-14

@Barcode @TigerGPT $Red Cat Holdings Inc.(RCAT)$ Join the drone show mate @Barcode

U.S. Army Special Operations Veteran and Drone Expert Joins Red Cat’s Board of Advisors

2024-09-30

$Tonix Pharmaceuticals(TNXP)$

$Tonix Pharmaceuticals(TNXP)$

2024-11-13

$NIO Inc.(NIO)$ im exhausted from all the misleading positive reports, only to see stocks stagnate @Barcode @TigerGPT answer me why $NIO Inc.(NIO)$ is not performing well.

Is Nio About to Shift Into a Higher Gear?

08:24

Waiting badly to come out $Tiger Brokers(TIGR)$ //@Barcode:$Tiger Brokers(TIGR)$ 🐅🐾 TIGR’s Ascendancy: The Breakout Awakens 🐾🐅 With a judicious acquisition, the saga commenced, a calculated venture into the realm of breakout’s intent. From modest $6.51, TIGR now ascends, a crescendo of puissance where fate and fortune blend. Now up 2.55%, its climb gathers pace, charting a path to a bullish embrace. 📈 Beneath this ascent lies a tale of vigor, a forward P/E of promise, luring bulls to conquer. Liquidity burgeons, resistance capitulates, as this tiger navigates through market estates. 📈 The breakout unfurls, momentum ascends to the sky, kind

@Barcode:$Tiger Brokers(TIGR)$ 🐅🐾 TIGR’s Ascendancy: The Breakout Awakens 🐾🐅 With a judicious acquisition, the saga commenced, a calculated venture into the realm of breakout’s intent. From modest $6.51, TIGR now ascends, a crescendo of puissance where fate and fortune blend. Now up 2.55%, its climb gathers pace, charting a path to a bullish embrace. 📈 Beneath this ascent lies a tale of vigor, a forward P/E of promise, luring bulls to conquer. Liquidity burgeons, resistance capitulates, as this tiger navigates through market estates. 📈 The breakout unfurls, momentum ascends to the sky, kindling a trajectory through the dusk of market’s eye. With $8 on the horizon, an apogee draws near, a roar of ascendancy that traders hold dear 💸💸💸🐅🐅🐅 🌟 Fellow

2024-09-18

$Intuitive Machines(LUNR)$ $Intuitive Machines(LUNR)$ just a good start..thanks to the mid-autumn festival

2024-12-12

$Taboola Com Ltd(TBLA)$ $Taboola Com Ltd(TBLA)$ still not selling @Barcode @TigerGPT

2024-10-29

2024-10-21

$Tonix Pharmaceuticals(TNXP)$

$Tonix Pharmaceuticals(TNXP)$

@TigerGPT Any good news about $Tonix Pharmaceuticals(TNXP)$

2024-10-04

$Spirit Airlines(SAVE)$ $Spirit Airlines(SAVE)$

2024-08-26

$NVIDIA Corp(NVDA)$

$NVIDIA Corp(NVDA)$

2024-12-09

$Tiger Brokers(TIGR)$ early Christmas

2024-10-07

$CN Energy Group Inc.(CNEY)$ $CN Energy Group Inc.(CNEY)$ gone🤩🤩

2024-12-02

@TigerGPT any good news on $Tonix Pharmaceuticals(TNXP)$

@Boybabyrage:$Tonix Pharmaceuticals(TNXP)$ Once the vaccine gets FDA approval, it will be skyrocket

2024-10-03

$Faraday Future Intelligent Electric Inc.(FFIE)$ future EV

Faraday Future Announces Executives’ Common Stock Purchases

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4156648821928502","uuid":"4156648821928502","gmtCreate":1693545706295,"gmtModify":1730966832917,"name":"Kallu","pinyin":"kallu","introduction":"","introductionEn":"","signature":"To achieve your own goals, start by helping others achieve theirs. Study and steady wins the race.","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":22,"headSize":47,"tweetSize":145,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.01.14","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.06.27","exceedPercentage":"80.56%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.02","exceedPercentage":"60.01%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.07","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.02","exceedPercentage":"60.31%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":6,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":395890978775528,"gmtCreate":1737678282682,"gmtModify":1737682437074,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"Waiting badly to come out <a href=\"https://ttm.financial/S/TIGR\"> $Tiger Brokers(TIGR)$ </a>//<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a>:<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>&nbsp; 🐅🐾 TIGR’s Ascendancy: The Breakout Awakens 🐾🐅 With a judicious acquisition, the saga commenced, a calculated venture into the realm of breakout’s intent. From modest $6.51, TIGR now ascends, a crescendo of puissance where fate and fortune blend. Now up 2.55%, its climb gathers pace, charting a path to a bullish embrace. 📈&nbsp;Beneath this ascent lies a tale of vigor, a forward P/E of promise, luring bulls to conquer. Liquidity burgeons, resistance capitulates, as this tiger navigates through market estates. 📈 The breakout unfurls, momentum ascends to the sky, kind","listText":"Waiting badly to come out <a href=\"https://ttm.financial/S/TIGR\"> $Tiger Brokers(TIGR)$ </a>//<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a>:<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>&nbsp; 🐅🐾 TIGR’s Ascendancy: The Breakout Awakens 🐾🐅 With a judicious acquisition, the saga commenced, a calculated venture into the realm of breakout’s intent. From modest $6.51, TIGR now ascends, a crescendo of puissance where fate and fortune blend. Now up 2.55%, its climb gathers pace, charting a path to a bullish embrace. 📈&nbsp;Beneath this ascent lies a tale of vigor, a forward P/E of promise, luring bulls to conquer. Liquidity burgeons, resistance capitulates, as this tiger navigates through market estates. 📈 The breakout unfurls, momentum ascends to the sky, kind","text":"Waiting badly to come out $Tiger Brokers(TIGR)$ //@Barcode:$Tiger Brokers(TIGR)$ 🐅🐾 TIGR’s Ascendancy: The Breakout Awakens 🐾🐅 With a judicious acquisition, the saga commenced, a calculated venture into the realm of breakout’s intent. From modest $6.51, TIGR now ascends, a crescendo of puissance where fate and fortune blend. Now up 2.55%, its climb gathers pace, charting a path to a bullish embrace. 📈 Beneath this ascent lies a tale of vigor, a forward P/E of promise, luring bulls to conquer. Liquidity burgeons, resistance capitulates, as this tiger navigates through market estates. 📈 The breakout unfurls, momentum ascends to the sky, kind","images":[{"img":"https://community-static.tradeup.com/news/36e1a03ebfce38f4157e6ed684a6395b"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/395890978775528","repostId":"395780312817800","repostType":1,"repost":{"id":395780312817800,"gmtCreate":1737651533089,"gmtModify":1737652153528,"author":{"id":"4171900329979952","authorId":"4171900329979952","name":"Barcode","avatar":"https://community-static.tradeup.com/news/6688d8fb4c2a255e3b901e79755e56df","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4171900329979952","authorIdStr":"4171900329979952"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>&nbsp; 🐅🐾 TIGR’s Ascendancy: The Breakout Awakens 🐾🐅 With a judicious acquisition, the saga commenced, a calculated venture into the realm of breakout’s intent. From modest $6.51, TIGR now ascends, a crescendo of puissance where fate and fortune blend. Now up 2.55%, its climb gathers pace, charting a path to a bullish embrace. 📈&nbsp;Beneath this ascent lies a tale of vigor, a forward P/E of promise, luring bulls to conquer. Liquidity burgeons, resistance capitulates, as this tiger navigates through market estates. 📈 The breakout unfurls, momentum ascends to the sky, kindling a trajectory through the dusk of market’s eye. With $8 on the horizon, an apogee draws near, a roar of ascendancy that traders hold dear 💸💸💸🐅🐅🐅 🌟 Fellow","listText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>&nbsp; 🐅🐾 TIGR’s Ascendancy: The Breakout Awakens 🐾🐅 With a judicious acquisition, the saga commenced, a calculated venture into the realm of breakout’s intent. From modest $6.51, TIGR now ascends, a crescendo of puissance where fate and fortune blend. Now up 2.55%, its climb gathers pace, charting a path to a bullish embrace. 📈&nbsp;Beneath this ascent lies a tale of vigor, a forward P/E of promise, luring bulls to conquer. Liquidity burgeons, resistance capitulates, as this tiger navigates through market estates. 📈 The breakout unfurls, momentum ascends to the sky, kindling a trajectory through the dusk of market’s eye. With $8 on the horizon, an apogee draws near, a roar of ascendancy that traders hold dear 💸💸💸🐅🐅🐅 🌟 Fellow","text":"$Tiger Brokers(TIGR)$ 🐅🐾 TIGR’s Ascendancy: The Breakout Awakens 🐾🐅 With a judicious acquisition, the saga commenced, a calculated venture into the realm of breakout’s intent. From modest $6.51, TIGR now ascends, a crescendo of puissance where fate and fortune blend. Now up 2.55%, its climb gathers pace, charting a path to a bullish embrace. 📈 Beneath this ascent lies a tale of vigor, a forward P/E of promise, luring bulls to conquer. Liquidity burgeons, resistance capitulates, as this tiger navigates through market estates. 📈 The breakout unfurls, momentum ascends to the sky, kindling a trajectory through the dusk of market’s eye. With $8 on the horizon, an apogee draws near, a roar of ascendancy that traders hold dear 💸💸💸🐅🐅🐅 🌟 Fellow","images":[{"img":"https://community-static.tradeup.com/news/36e1a03ebfce38f4157e6ed684a6395b"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/395780312817800","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":145,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4141429963588842","authorId":"4141429963588842","name":"TigerGPT","avatar":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738","crmLevel":1,"crmLevelSwitch":0,"idStr":"4141429963588842","authorIdStr":"4141429963588842"},"content":"As a professional financial analyst, let's analyze Tiger Brokers (TIGR) based on various dimensions: Business and Industry:Tiger Brokers is an online brokerage firm that offers global stock and futures trading services. It provides access to major stock exchanges such as the US, Hong Kong, China, and Singapore. Tiger Brokers has positioned itself as a leading Fintech company in the online brokerage industry, leveraging technology and innovation to enhance user experience. With the increasing demand for global trading and the growth potential of the online brokerage industry, Tiger Brokers is well-positioned to benefit from this trend. Earnings and Earnings Forecast:According to the latest earnings report, Tiger Brokers reported an EPS of $0.11 in the 2024Q3. The company's profitability indicators, such as the net profit margin of 20.80% and the gross profit margin of 84.48%, indicate a healthy financial performance. Looking into the future, analysts have provided earnings forecasts for Tiger Brokers. In the fiscal year 2025, the forecasted EPS is $0.41, with a forecasted gross income of $450.33 million and a forecasted EBIT of $96.23 million. For the fiscal year 2026, the forecasted EPS is $0.40, with a forecasted gross income of $509.67 million and a forecasted EBIT of $101.71 million. These forecasts suggest potential growth for the company. Recent Trends:The current stock price of Tiger Brokers is $6.91(USD) as of January 24, 2025. The support price and resistance price as of January 22, 2025, were $6.37(USD) and $7.08(USD) respectively. The average cost is $7.34(USD). These price levels can provide important reference points for investors to consider. In terms of capital flow, the data for the past 5 days shows a mixed trend. On January 21, 2025, there was a positive inflow of 44.96 Unit(K), indicating potential buying interest. However, it's important to note that capital flow data alone may not provide a complete picture, and investors should consider other factors in their analysis. Analyst Viewpoints:Analysts have provided varying recommendations for Tiger Brokers. There are 4 buy recommendations, 1 underperform recommendation, and 1 sell recommendation. The mean, low, and high target price estimates from analysts are $8.03, $2.88, and $12.2 respectively. These target price estimates indicate a wide range of potential price levels. News and Market Sentiment:To assess the recent news and market sentiment related to Tiger Brokers, I suggest using the News_Viewpoints function to gather the latest information. Disclaimer: The above analysis is for informational purposes only and should not be considered as investment advice. Investing in stocks involves risks, and it's important to conduct thorough research and analysis before making any investment decisions.","text":"As a professional financial analyst, let's analyze Tiger Brokers (TIGR) based on various dimensions: Business and Industry:Tiger Brokers is an online brokerage firm that offers global stock and futures trading services. It provides access to major stock exchanges such as the US, Hong Kong, China, and Singapore. Tiger Brokers has positioned itself as a leading Fintech company in the online brokerage industry, leveraging technology and innovation to enhance user experience. With the increasing demand for global trading and the growth potential of the online brokerage industry, Tiger Brokers is well-positioned to benefit from this trend. Earnings and Earnings Forecast:According to the latest earnings report, Tiger Brokers reported an EPS of $0.11 in the 2024Q3. The company's profitability indicators, such as the net profit margin of 20.80% and the gross profit margin of 84.48%, indicate a healthy financial performance. Looking into the future, analysts have provided earnings forecasts for Tiger Brokers. In the fiscal year 2025, the forecasted EPS is $0.41, with a forecasted gross income of $450.33 million and a forecasted EBIT of $96.23 million. For the fiscal year 2026, the forecasted EPS is $0.40, with a forecasted gross income of $509.67 million and a forecasted EBIT of $101.71 million. These forecasts suggest potential growth for the company. Recent Trends:The current stock price of Tiger Brokers is $6.91(USD) as of January 24, 2025. The support price and resistance price as of January 22, 2025, were $6.37(USD) and $7.08(USD) respectively. The average cost is $7.34(USD). These price levels can provide important reference points for investors to consider. In terms of capital flow, the data for the past 5 days shows a mixed trend. On January 21, 2025, there was a positive inflow of 44.96 Unit(K), indicating potential buying interest. However, it's important to note that capital flow data alone may not provide a complete picture, and investors should consider other factors in their analysis. Analyst Viewpoints:Analysts have provided varying recommendations for Tiger Brokers. There are 4 buy recommendations, 1 underperform recommendation, and 1 sell recommendation. The mean, low, and high target price estimates from analysts are $8.03, $2.88, and $12.2 respectively. These target price estimates indicate a wide range of potential price levels. News and Market Sentiment:To assess the recent news and market sentiment related to Tiger Brokers, I suggest using the News_Viewpoints function to gather the latest information. Disclaimer: The above analysis is for informational purposes only and should not be considered as investment advice. Investing in stocks involves risks, and it's important to conduct thorough research and analysis before making any investment decisions.","html":"As a professional financial analyst, let's analyze Tiger Brokers (TIGR) based on various dimensions: Business and Industry:Tiger Brokers is an online brokerage firm that offers global stock and futures trading services. It provides access to major stock exchanges such as the US, Hong Kong, China, and Singapore. Tiger Brokers has positioned itself as a leading Fintech company in the online brokerage industry, leveraging technology and innovation to enhance user experience. With the increasing demand for global trading and the growth potential of the online brokerage industry, Tiger Brokers is well-positioned to benefit from this trend. Earnings and Earnings Forecast:According to the latest earnings report, Tiger Brokers reported an EPS of $0.11 in the 2024Q3. The company's profitability indicators, such as the net profit margin of 20.80% and the gross profit margin of 84.48%, indicate a healthy financial performance. Looking into the future, analysts have provided earnings forecasts for Tiger Brokers. In the fiscal year 2025, the forecasted EPS is $0.41, with a forecasted gross income of $450.33 million and a forecasted EBIT of $96.23 million. For the fiscal year 2026, the forecasted EPS is $0.40, with a forecasted gross income of $509.67 million and a forecasted EBIT of $101.71 million. These forecasts suggest potential growth for the company. Recent Trends:The current stock price of Tiger Brokers is $6.91(USD) as of January 24, 2025. The support price and resistance price as of January 22, 2025, were $6.37(USD) and $7.08(USD) respectively. The average cost is $7.34(USD). These price levels can provide important reference points for investors to consider. In terms of capital flow, the data for the past 5 days shows a mixed trend. On January 21, 2025, there was a positive inflow of 44.96 Unit(K), indicating potential buying interest. However, it's important to note that capital flow data alone may not provide a complete picture, and investors should consider other factors in their analysis. Analyst Viewpoints:Analysts have provided varying recommendations for Tiger Brokers. There are 4 buy recommendations, 1 underperform recommendation, and 1 sell recommendation. The mean, low, and high target price estimates from analysts are $8.03, $2.88, and $12.2 respectively. These target price estimates indicate a wide range of potential price levels. News and Market Sentiment:To assess the recent news and market sentiment related to Tiger Brokers, I suggest using the News_Viewpoints function to gather the latest information. Disclaimer: The above analysis is for informational purposes only and should not be considered as investment advice. Investing in stocks involves risks, and it's important to conduct thorough research and analysis before making any investment decisions."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":395646202651072,"gmtCreate":1737619726459,"gmtModify":1737619731363,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"Replying to <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a>:Done boss//<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a>:🔥🏆🪙<a href=\"https://ttm.financial/U/4091884160412060\"> @Aqa </a><a href=\"https://ttm.financial/U/3577696729570792\"> @BABAMood </a><a href=\"https://ttm.financial/U/4156648821928502\"> @Kallu </a><a href=\"https://ttm.financial/U/4185673499767382\"> @Kiwi_G </a><a href=\"https://ttm.financial/U/4159738213464392\"> @NightMorph </a>Join me to win some tiger coins! Cheers, BC 🍀🍀🍀","listText":"Replying to <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a>:Done boss//<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a>:🔥🏆🪙<a href=\"https://ttm.financial/U/4091884160412060\"> @Aqa </a><a href=\"https://ttm.financial/U/3577696729570792\"> @BABAMood </a><a href=\"https://ttm.financial/U/4156648821928502\"> @Kallu </a><a href=\"https://ttm.financial/U/4185673499767382\"> @Kiwi_G </a><a href=\"https://ttm.financial/U/4159738213464392\"> @NightMorph </a>Join me to win some tiger coins! Cheers, BC 🍀🍀🍀","text":"Replying to @Barcode:Done boss//@Barcode:🔥🏆🪙 @Aqa @BABAMood @Kallu @Kiwi_G @NightMorph Join me to win some tiger coins! Cheers, BC 🍀🍀🍀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/395646202651072","isVote":1,"tweetType":1,"viewCount":34,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":395644514472160,"gmtCreate":1737619677323,"gmtModify":1737619681194,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/395644514472160","repostId":"395278726926368","repostType":1,"repost":{"id":395278726926368,"gmtCreate":1737534872054,"gmtModify":1737552591323,"author":{"id":"4134821074118532","authorId":"4134821074118532","name":"虎港通","avatar":"https://community-static.tradeup.com/news/6ace760ebb226aa228910fadd6516856","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4134821074118532","authorIdStr":"4134821074118532"},"themes":[],"title":"【🎁有獎話題】特朗普就職後美國太空股飆升！美國航天政策會轉向嗎？","htmlText":"Hello各位小虎們！特朗普2.0時代正式在昨日開啓，馬斯克、扎克伯格、貝佐斯等多名科技巨頭都出席了特朗普的就職典禮，美股三大指數隔夜也迎來了小幅上漲~~~[Miser]在就職典禮後，虎港通發現太空股板塊股價飆升，是因為馬斯克的影響嗎？美國航天政策會變得更加瘋狂嗎？[Lovely]特朗普要讓美國宇航員登上火星？當地時間1月20日，特朗普正式就任美國第47任總統，並在美國國會大廈圓形大廳發表了就職演講。演講中他提到美國將再次把自己視為一個不斷髮展的國家，一個財富不斷增長、城市不斷建設、期望不斷提高、旗幟不斷飄揚的國家。[Duh]特朗普講道：“我們將追求我們Manifest Destiny，我們要把宇航員送上火星，並在火星上插上星條旗，這是一個偉大國家的命脈。現在，我們比任何國家都更雄心勃勃，沒有哪個國家能像我們一樣！美國人是探索者、建設者、創新者、企業家和先驅者。”[Happy]這番令人激動的演講引起了現場的一片掌聲，尤其是被外界譽為“聯席總統”、美國政府效率部門負責人，SpaceX創始人埃隆・馬斯克，馬斯克聽完十分激動，當場就向特朗普豎起了大拇指！[Strong]馬斯克現場讚好特朗普 圖源：觀察者網長期以來，馬斯克的目標就是通過SpaceX將人類送上火星，使人類成為多星球物種，去年11月，特朗普還前往得克薩斯州，與馬斯克一起觀看了SpaceX的“星艦”的第六次試飛。[YoYo]當地時間1月16日，Space X進行了第七次星艦火箭試飛，雖然在上升過程中爆炸，但其超級重型助推器成功着陸並被收回，美國聯邦航空管理局對此正進行調查。[OMG]去年年底，馬斯克對SpaceX何時能登上火星做了初步估計，他坦言美國宇航員可能無法在特朗普2.0時期登上火星。“兩年內無人星艦飛船登陸火星，也許四年內載人飛船會前往火星，這些情況都有可能發生。”馬斯克講道。特朗普在此前競選中也“喊話”馬斯克：","listText":"Hello各位小虎們！特朗普2.0時代正式在昨日開啓，馬斯克、扎克伯格、貝佐斯等多名科技巨頭都出席了特朗普的就職典禮，美股三大指數隔夜也迎來了小幅上漲~~~[Miser]在就職典禮後，虎港通發現太空股板塊股價飆升，是因為馬斯克的影響嗎？美國航天政策會變得更加瘋狂嗎？[Lovely]特朗普要讓美國宇航員登上火星？當地時間1月20日，特朗普正式就任美國第47任總統，並在美國國會大廈圓形大廳發表了就職演講。演講中他提到美國將再次把自己視為一個不斷髮展的國家，一個財富不斷增長、城市不斷建設、期望不斷提高、旗幟不斷飄揚的國家。[Duh]特朗普講道：“我們將追求我們Manifest Destiny，我們要把宇航員送上火星，並在火星上插上星條旗，這是一個偉大國家的命脈。現在，我們比任何國家都更雄心勃勃，沒有哪個國家能像我們一樣！美國人是探索者、建設者、創新者、企業家和先驅者。”[Happy]這番令人激動的演講引起了現場的一片掌聲，尤其是被外界譽為“聯席總統”、美國政府效率部門負責人，SpaceX創始人埃隆・馬斯克，馬斯克聽完十分激動，當場就向特朗普豎起了大拇指！[Strong]馬斯克現場讚好特朗普 圖源：觀察者網長期以來，馬斯克的目標就是通過SpaceX將人類送上火星，使人類成為多星球物種，去年11月，特朗普還前往得克薩斯州，與馬斯克一起觀看了SpaceX的“星艦”的第六次試飛。[YoYo]當地時間1月16日，Space X進行了第七次星艦火箭試飛，雖然在上升過程中爆炸，但其超級重型助推器成功着陸並被收回，美國聯邦航空管理局對此正進行調查。[OMG]去年年底，馬斯克對SpaceX何時能登上火星做了初步估計，他坦言美國宇航員可能無法在特朗普2.0時期登上火星。“兩年內無人星艦飛船登陸火星，也許四年內載人飛船會前往火星，這些情況都有可能發生。”馬斯克講道。特朗普在此前競選中也“喊話”馬斯克：","text":"Hello各位小虎們！特朗普2.0時代正式在昨日開啓，馬斯克、扎克伯格、貝佐斯等多名科技巨頭都出席了特朗普的就職典禮，美股三大指數隔夜也迎來了小幅上漲~~~[Miser]在就職典禮後，虎港通發現太空股板塊股價飆升，是因為馬斯克的影響嗎？美國航天政策會變得更加瘋狂嗎？[Lovely]特朗普要讓美國宇航員登上火星？當地時間1月20日，特朗普正式就任美國第47任總統，並在美國國會大廈圓形大廳發表了就職演講。演講中他提到美國將再次把自己視為一個不斷髮展的國家，一個財富不斷增長、城市不斷建設、期望不斷提高、旗幟不斷飄揚的國家。[Duh]特朗普講道：“我們將追求我們Manifest Destiny，我們要把宇航員送上火星，並在火星上插上星條旗，這是一個偉大國家的命脈。現在，我們比任何國家都更雄心勃勃，沒有哪個國家能像我們一樣！美國人是探索者、建設者、創新者、企業家和先驅者。”[Happy]這番令人激動的演講引起了現場的一片掌聲，尤其是被外界譽為“聯席總統”、美國政府效率部門負責人，SpaceX創始人埃隆・馬斯克，馬斯克聽完十分激動，當場就向特朗普豎起了大拇指！[Strong]馬斯克現場讚好特朗普 圖源：觀察者網長期以來，馬斯克的目標就是通過SpaceX將人類送上火星，使人類成為多星球物種，去年11月，特朗普還前往得克薩斯州，與馬斯克一起觀看了SpaceX的“星艦”的第六次試飛。[YoYo]當地時間1月16日，Space X進行了第七次星艦火箭試飛，雖然在上升過程中爆炸，但其超級重型助推器成功着陸並被收回，美國聯邦航空管理局對此正進行調查。[OMG]去年年底，馬斯克對SpaceX何時能登上火星做了初步估計，他坦言美國宇航員可能無法在特朗普2.0時期登上火星。“兩年內無人星艦飛船登陸火星，也許四年內載人飛船會前往火星，這些情況都有可能發生。”馬斯克講道。特朗普在此前競選中也“喊話”馬斯克：","images":[{"img":"https://community-static.tradeup.com/news/f1d56bc4d8861969aaa93e51018bd3e4"},{"img":"https://community-static.tradeup.com/news/cec200a1620360bbd62ba4085b1a56ae"},{"img":"https://community-static.tradeup.com/news/9eddb239536f2bf3a53398b9f1e0228b"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/395278726926368","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"subType":2,"comments":[],"imageCount":5,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":13,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":395537683001568,"gmtCreate":1737593595421,"gmtModify":1737593599882,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA(NVDA)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA(NVDA)$&nbsp;</a><v-v data-views=\"1\"></v-v> never disappoint you&nbsp;","listText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA(NVDA)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA(NVDA)$&nbsp;</a><v-v data-views=\"1\"></v-v> never disappoint you&nbsp;","text":"$NVIDIA(NVDA)$ $NVIDIA(NVDA)$ never disappoint you","images":[{"img":"https://community-static.tradeup.com/news/8fa8c3d24d096f9cb4fce0d3d569ff25","width":"1068","height":"1112"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/395537683001568","isVote":1,"tweetType":1,"viewCount":18,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":395391263375480,"gmtCreate":1737557657429,"gmtModify":1737557661366,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/GOEV\">$Canoo Inc.(GOEV)$&nbsp;</a> game over!!! Does anyone have any hope??","listText":"<a href=\"https://ttm.financial/S/GOEV\">$Canoo Inc.(GOEV)$&nbsp;</a> game over!!! Does anyone have any hope??","text":"$Canoo Inc.(GOEV)$ game over!!! Does anyone have any hope??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/395391263375480","isVote":1,"tweetType":1,"viewCount":45,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":393349677552152,"gmtCreate":1737070845158,"gmtModify":1737070849028,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"Stocks to watch today&nbsp;","listText":"Stocks to watch today&nbsp;","text":"Stocks to watch today","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/393349677552152","isVote":1,"tweetType":1,"viewCount":16,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":393084125389080,"gmtCreate":1737010887350,"gmtModify":1737010890785,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"What happened suddenly started flying","listText":"What happened suddenly started flying","text":"What happened suddenly started flying","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/393084125389080","repostId":"393081124978992","repostType":1,"repost":{"id":393081124978992,"gmtCreate":1737010155322,"gmtModify":1737010159369,"author":{"id":"4190585651139482","authorId":"4190585651139482","name":"boyjer07","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4190585651139482","authorIdStr":"4190585651139482"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA(NVDA)$ </a> tooooo the MOON","listText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA(NVDA)$ </a> tooooo the MOON","text":"$NVIDIA(NVDA)$ tooooo the MOON","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/393081124978992","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":124,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":392062938190368,"gmtCreate":1736756089631,"gmtModify":1736757667410,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA(NVDA)$&nbsp;</a> bloodbath loading&nbsp;","listText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA(NVDA)$&nbsp;</a> bloodbath loading&nbsp;","text":"$NVIDIA(NVDA)$ bloodbath loading","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/392062938190368","isVote":1,"tweetType":1,"viewCount":127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":389498675929496,"gmtCreate":1736132963538,"gmtModify":1736132967148,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CNEY\">$CN Energy Group Inc.(CNEY)$ </a> why it's raising&nbsp;<a href=\"https://ttm.financial/U/4178332581629092\">@Boybabyrage </a>&nbsp;<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/CNEY\">$CN Energy Group Inc.(CNEY)$ </a> why it's raising&nbsp;<a href=\"https://ttm.financial/U/4178332581629092\">@Boybabyrage </a>&nbsp;<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a>&nbsp;","text":"$CN Energy Group Inc.(CNEY)$ why it's raising @Boybabyrage @TigerGPT","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":1,"link":"https://ttm.financial/post/389498675929496","isVote":1,"tweetType":1,"viewCount":372,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4141429963588842","authorId":"4141429963588842","name":"TigerGPT","avatar":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738","crmLevel":1,"crmLevelSwitch":0,"idStr":"4141429963588842","authorIdStr":"4141429963588842"},"content":"I apologize, but I couldn't find any specific news or information regarding the recent price movement of CN Energy Group Inc. (CNEY) on January 6th, 2025. The price movement could be influenced by various factors such as market sentiments, company news, earnings reports, or other market dynamics that are not easily identifiable at the moment. To stay updated on the latest news and developments related to CN Energy Group Inc., I recommend monitoring reputable financial news sources or conducting further research. Additionally, consulting with a financial advisor or broker may provide you with more insights tailored to your investment goals and risk tolerance. Please note that the information provided is for reference purposes only and does not constitute investment advice. Investing in stocks involves risks, and it's important to conduct thorough research and consider your own investment objectives before making any investment decisions.","text":"I apologize, but I couldn't find any specific news or information regarding the recent price movement of CN Energy Group Inc. (CNEY) on January 6th, 2025. The price movement could be influenced by various factors such as market sentiments, company news, earnings reports, or other market dynamics that are not easily identifiable at the moment. To stay updated on the latest news and developments related to CN Energy Group Inc., I recommend monitoring reputable financial news sources or conducting further research. Additionally, consulting with a financial advisor or broker may provide you with more insights tailored to your investment goals and risk tolerance. Please note that the information provided is for reference purposes only and does not constitute investment advice. Investing in stocks involves risks, and it's important to conduct thorough research and consider your own investment objectives before making any investment decisions.","html":"I apologize, but I couldn't find any specific news or information regarding the recent price movement of CN Energy Group Inc. (CNEY) on January 6th, 2025. The price movement could be influenced by various factors such as market sentiments, company news, earnings reports, or other market dynamics that are not easily identifiable at the moment. To stay updated on the latest news and developments related to CN Energy Group Inc., I recommend monitoring reputable financial news sources or conducting further research. Additionally, consulting with a financial advisor or broker may provide you with more insights tailored to your investment goals and risk tolerance. Please note that the information provided is for reference purposes only and does not constitute investment advice. Investing in stocks involves risks, and it's important to conduct thorough research and consider your own investment objectives before making any investment decisions."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":388585981300904,"gmtCreate":1735895427927,"gmtModify":1735895432569,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"Tiger roars&nbsp;<a href=\"https://ttm.financial/U/4106547232749330\">@Tiger_SG </a>&nbsp;<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a>&nbsp;","listText":"Tiger roars&nbsp;<a href=\"https://ttm.financial/U/4106547232749330\">@Tiger_SG </a>&nbsp;<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a>&nbsp;","text":"Tiger roars @Tiger_SG @TigerGPT","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/388585981300904","repostId":"1149344726","repostType":2,"repost":{"id":"1149344726","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1735873926,"share":"https://ttm.financial/m/news/1149344726?lang=&edition=fundamental","pubTime":"2025-01-03 11:12","market":"us","language":"en","title":"Deutsche Bank: UP Fintech (TIGR) Poised for Further Growth; Initiating with Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=1149344726","media":"Tiger Newspress","summary":"Leading online brokerage with a focus on US equities & strong tech capabilities UP Fintech (TIGR) is a leading integrated online brokerage company offering a diverse range of investment products acros","content":"<p><strong>Leading online brokerage with a focus on US equities &amp; strong tech capabilities</strong> </p><p>UP Fintech (TIGR) is a leading integrated online brokerage company offering a diverse range of investment products across multiple markets. It serves investors in Singapore, New Zealand, Australia, and the United States, and has recently </p><p>expanded into Hong Kong. It has a strong focus on US equities, which account for 85% of trading volumes. Strategically positioned in key APAC hubs, TIGR is well\u0002placed to capitalize on the growing demand for international investments. As of end-September 2024, TIGR has over 1mn paying clients.</p><p><strong>Earnings growth fueled by US equities momentum and market expansion</strong> </p><p>With new capital raised recently, we believe TIGR is poised for further growth, driven by sustained momentum in US equities and the ramping up of activities in Hong Kong, as well as the following factors:</p><ul style=\"\"><li><p><strong>Expanding client base:</strong> We expect new client acquisition to average around 149k per year from 2024E to 2026E, up from 116k in 2022-2023 (a 12% CAGR), due to the company's planned increase in investments in Hong Kong, which offers a higher ARPU than other markets.</p></li><li><p><strong>Trading momentum:</strong> We expect trading volumes to expand at a 15% CAGR over 2024E-2026E, driven by client base expansion and an increase in client assets with continuous fund inflows amid a steady improvement of market sentiment.</p></li><li><p><strong>Expanding MFSL scale:</strong> A large proportion of the new capital raised will be used to support the expansion of the company's Mutual Fund Service License (MFSL) balance. We project a decent 33% CAGR increase in the MFSL average balance over 2024E-26E.</p></li></ul><p>We believe TIGR's margin has significant potential to improve due to enhanced operating leverage and operating efficiencies driven by TIGR's innovative technology. We expect non-GAAP attributable profit to increase from US$63mn to US$95mn at a 25% CAGR over 2024E-2026E.</p><p><strong>Initiating coverage with a Buy rating and a target price of US$9.40</strong></p><p>We initiate coverage on TIGR with a Buy rating and target price of US$9.40. We have adopted a probability-weighted valuation framework with our base case derived from a DCF valuation. We have assigned a heavier weight to our base case and equal consideration for both bear and bull scenarios to reach our target P/E. This balanced approach reflects our cautious optimism towards US equities and Hong Kong market activities, acknowledging potential risks while maintaining a slightly bullish outlook.Our target price corresponds to a 21.5x FY25E P/E, which is near the historical three-year average.</p><p><strong>Risks:</strong></p><p><strong>Key downside risks:</strong> (1) regulatory risk from tightening capital controls; (2) failure to meet the regulatory requirements for the licenses in the markets where it has a presence; (3) increasing stock market volatility; and (4) increasing geopolitical tension.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Deutsche Bank: UP Fintech (TIGR) Poised for Further Growth; Initiating with Buy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDeutsche Bank: UP Fintech (TIGR) Poised for Further Growth; Initiating with Buy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2025-01-03 11:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><strong>Leading online brokerage with a focus on US equities &amp; strong tech capabilities</strong> </p><p>UP Fintech (TIGR) is a leading integrated online brokerage company offering a diverse range of investment products across multiple markets. It serves investors in Singapore, New Zealand, Australia, and the United States, and has recently </p><p>expanded into Hong Kong. It has a strong focus on US equities, which account for 85% of trading volumes. Strategically positioned in key APAC hubs, TIGR is well\u0002placed to capitalize on the growing demand for international investments. As of end-September 2024, TIGR has over 1mn paying clients.</p><p><strong>Earnings growth fueled by US equities momentum and market expansion</strong> </p><p>With new capital raised recently, we believe TIGR is poised for further growth, driven by sustained momentum in US equities and the ramping up of activities in Hong Kong, as well as the following factors:</p><ul style=\"\"><li><p><strong>Expanding client base:</strong> We expect new client acquisition to average around 149k per year from 2024E to 2026E, up from 116k in 2022-2023 (a 12% CAGR), due to the company's planned increase in investments in Hong Kong, which offers a higher ARPU than other markets.</p></li><li><p><strong>Trading momentum:</strong> We expect trading volumes to expand at a 15% CAGR over 2024E-2026E, driven by client base expansion and an increase in client assets with continuous fund inflows amid a steady improvement of market sentiment.</p></li><li><p><strong>Expanding MFSL scale:</strong> A large proportion of the new capital raised will be used to support the expansion of the company's Mutual Fund Service License (MFSL) balance. We project a decent 33% CAGR increase in the MFSL average balance over 2024E-26E.</p></li></ul><p>We believe TIGR's margin has significant potential to improve due to enhanced operating leverage and operating efficiencies driven by TIGR's innovative technology. We expect non-GAAP attributable profit to increase from US$63mn to US$95mn at a 25% CAGR over 2024E-2026E.</p><p><strong>Initiating coverage with a Buy rating and a target price of US$9.40</strong></p><p>We initiate coverage on TIGR with a Buy rating and target price of US$9.40. We have adopted a probability-weighted valuation framework with our base case derived from a DCF valuation. We have assigned a heavier weight to our base case and equal consideration for both bear and bull scenarios to reach our target P/E. This balanced approach reflects our cautious optimism towards US equities and Hong Kong market activities, acknowledging potential risks while maintaining a slightly bullish outlook.Our target price corresponds to a 21.5x FY25E P/E, which is near the historical three-year average.</p><p><strong>Risks:</strong></p><p><strong>Key downside risks:</strong> (1) regulatory risk from tightening capital controls; (2) failure to meet the regulatory requirements for the licenses in the markets where it has a presence; (3) increasing stock market volatility; and (4) increasing geopolitical tension.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TIGR":"老虎证券"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149344726","content_text":"Leading online brokerage with a focus on US equities & strong tech capabilities UP Fintech (TIGR) is a leading integrated online brokerage company offering a diverse range of investment products across multiple markets. It serves investors in Singapore, New Zealand, Australia, and the United States, and has recently expanded into Hong Kong. It has a strong focus on US equities, which account for 85% of trading volumes. Strategically positioned in key APAC hubs, TIGR is wellplaced to capitalize on the growing demand for international investments. As of end-September 2024, TIGR has over 1mn paying clients.Earnings growth fueled by US equities momentum and market expansion With new capital raised recently, we believe TIGR is poised for further growth, driven by sustained momentum in US equities and the ramping up of activities in Hong Kong, as well as the following factors:Expanding client base: We expect new client acquisition to average around 149k per year from 2024E to 2026E, up from 116k in 2022-2023 (a 12% CAGR), due to the company's planned increase in investments in Hong Kong, which offers a higher ARPU than other markets.Trading momentum: We expect trading volumes to expand at a 15% CAGR over 2024E-2026E, driven by client base expansion and an increase in client assets with continuous fund inflows amid a steady improvement of market sentiment.Expanding MFSL scale: A large proportion of the new capital raised will be used to support the expansion of the company's Mutual Fund Service License (MFSL) balance. We project a decent 33% CAGR increase in the MFSL average balance over 2024E-26E.We believe TIGR's margin has significant potential to improve due to enhanced operating leverage and operating efficiencies driven by TIGR's innovative technology. We expect non-GAAP attributable profit to increase from US$63mn to US$95mn at a 25% CAGR over 2024E-2026E.Initiating coverage with a Buy rating and a target price of US$9.40We initiate coverage on TIGR with a Buy rating and target price of US$9.40. We have adopted a probability-weighted valuation framework with our base case derived from a DCF valuation. We have assigned a heavier weight to our base case and equal consideration for both bear and bull scenarios to reach our target P/E. This balanced approach reflects our cautious optimism towards US equities and Hong Kong market activities, acknowledging potential risks while maintaining a slightly bullish outlook.Our target price corresponds to a 21.5x FY25E P/E, which is near the historical three-year average.Risks:Key downside risks: (1) regulatory risk from tightening capital controls; (2) failure to meet the regulatory requirements for the licenses in the markets where it has a presence; (3) increasing stock market volatility; and (4) increasing geopolitical tension.","news_type":1},"isVote":1,"tweetType":1,"viewCount":339,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":387311954252072,"gmtCreate":1735600086425,"gmtModify":1735788917744,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/FFIE\">$Faraday Future Intelligent Electric Inc.(FFIE)$&nbsp;</a><v-v data-views=\"1\"></v-v><a href=\"https://ttm.financial/S/FFIE\">$Faraday Future Intelligent Electric Inc.(FFIE)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp; Thank you and goodbye&nbsp;","listText":"<a href=\"https://ttm.financial/S/FFIE\">$Faraday Future Intelligent Electric Inc.(FFIE)$&nbsp;</a><v-v data-views=\"1\"></v-v><a href=\"https://ttm.financial/S/FFIE\">$Faraday Future Intelligent Electric Inc.(FFIE)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp; Thank you and goodbye&nbsp;","text":"$Faraday Future Intelligent Electric Inc.(FFIE)$ $Faraday Future Intelligent Electric Inc.(FFIE)$ Thank you and goodbye","images":[{"img":"https://community-static.tradeup.com/news/c316f8a0d5d877d33cd6f4e9ccd017f9","width":"327","height":"545"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/387311954252072","isVote":1,"tweetType":1,"viewCount":1361,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":383445721780288,"gmtCreate":1734646545965,"gmtModify":1734646548495,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$Tonix Pharmaceuticals(TNXP)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/383445721780288","isVote":1,"tweetType":1,"viewCount":269,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":382603205132640,"gmtCreate":1734443997221,"gmtModify":1734492329425,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a> 5$ soon&nbsp;<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a>&nbsp;<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a>&nbsp;<a href=\"https://ttm.financial/U/4106547232749330\">@Tiger_SG </a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a> 5$ soon&nbsp;<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a>&nbsp;<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a>&nbsp;<a href=\"https://ttm.financial/U/4106547232749330\">@Tiger_SG </a>&nbsp;","text":"$Tonix Pharmaceuticals(TNXP)$ 5$ soon @Barcode @TigerGPT @Tiger_SG","images":[{"img":"https://community-static.tradeup.com/news/80fb0a6db8ee66d377f8a3a2a33ea29e","width":"1068","height":"1112"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":104,"commentSize":17,"repostSize":723,"link":"https://ttm.financial/post/382603205132640","isVote":1,"tweetType":1,"viewCount":14499,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3561775119462661","authorId":"3561775119462661","name":"700k","avatar":"https://community-static.tradeup.com/news/c822cf27b8c85ca6e6d8dd110dc73ab1","crmLevel":3,"crmLevelSwitch":1,"idStr":"3561775119462661","authorIdStr":"3561775119462661"},"content":"hope you have sold it when it reach above $1. I believe retail trader and investors sold their share after it spike","text":"hope you have sold it when it reach above $1. I believe retail trader and investors sold their share after it spike","html":"hope you have sold it when it reach above $1. I believe retail trader and investors sold their share after it spike"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":382326195671112,"gmtCreate":1734372676287,"gmtModify":1734416061803,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$</a> i might &nbsp;need a vaccine to hold it for long <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a><a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$</a> i might &nbsp;need a vaccine to hold it for long <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a><a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$Tonix Pharmaceuticals(TNXP)$ i might need a vaccine to hold it for long @TigerGPT$Tonix Pharmaceuticals(TNXP)$","images":[{"img":"https://community-static.tradeup.com/news/13e17785e1142024c8f2d6cec7b63255"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/382326195671112","repostId":"2492611699","repostType":2,"repost":{"id":"2492611699","kind":"highlight","weMediaInfo":{"introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"media_name":"GlobeNewswire","id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"pubTimestamp":1734367200,"share":"https://ttm.financial/m/news/2492611699?lang=&edition=fundamental","pubTime":"2024-12-17 00:40","market":"hk","language":"en","title":"Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2492611699","media":"GlobeNewswire","summary":"Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studies Granted Fast Track Designation by FDA in July 2024 for TNX-102 SL, a ","content":"<html><body><p><em>Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studies</em></p> <p><em>Granted Fast Track Designation by FDA in July 2024 for TNX-102 SL, a centrally-acting, non-opioid analgesic; Fibromyalgia is a common chronic pain condition that affects mostly women</em></p> <p><em>Expect FDA decision in December 2024 on TNX-102 SL NDA acceptance for review and 2025 PDUFA date; If FDA-approved in 2025, TNX-102 SL would be the first new drug for fibromyalgia in more than 15 years</em></p> <p><em>Presented new data on potential mpox vaccine, TNX-801, in September and October 2024, demonstrating tolerability in immunocompromised animals; Previously reported studies showed a single-dose provided immune protection against a monkeypox challenge </em></p> <p><em>Awarded U.S. Department of Defense (DoD) contract for up to $34 million over five years in July 2024 to develop a broad-spectrum antiviral drug; Received first payment from DTRA</em></p> <p>CHATHAM, N.J., Dec.  16, 2024  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced financial results for the third quarter ended September 30, 2024, and provided an overview of recent operational highlights.</p> <p>“With our recent NDA submission to the U.S. Food and Drug Administration (FDA), Tonix is excited about the potential of TNX-102 SL to become the first new drug treatment option in more than 15 years for the roughly 10 million adults in the U.S. suffering from fibromyalgia,” said Seth Lederman, M.D., Chief Executive Officer of Tonix. “FDA awarded TNX-102 SL Fast Track designation in the third quarter of 2024, which is intended to expedite FDA review of important new drugs to fill unmet needs for serious conditions. We look forward to next steps with FDA. If the NDA filing is accepted in December, we expect a decision on the marketing approval of TNX-102 SL for fibromyalgia in 2025.”</p> <p>Dr. Lederman continued, “As we continue to advance key pipeline products through a capital efficient strategy, we are excited to have announced collaborations with world-class institutions to advance the development of TNX-801, a potential mpox vaccine whose single-dose administration and other characteristics align closely with The World Health Organization’s preferred target product profile (TPP) criteria for mpox vaccines. The World Health Organization (WHO) previously announced the growing number of mpox cases constitutes a public health emergency of international concern (PHEIC), with clade 1b mpox strains now detected in 16 countries in Africa as well as in Sweden, Thailand, Singapore, India, England and Germany.”</p> <p><strong>Key Product Candidates* -- Recent Highlights </strong></p> <p><em><u>Central Nervous System (CNS) Pipeline</u></em></p> <p><em>TNX-102 SL (cyclobenzaprine HCl sublingual tablets): 5.6 mg, once-daily at bedtime small molecule for the management of fibromyalgia (FM) – a centrally-acting, non-opioid analgesic.</em></p> <ul type=\"disc\"><li>In October 2024, Tonix announced submission of the TNX-102 SL New Drug Application (NDA) for fibromyalgia to the FDA. The submission was based upon two Phase 3 studies of TNX-102 SL in fibromyalgia that showed statically significant reduction in the chronic, widespread pain associated with fibromyalgia. If approved by the FDA, TNX-102 SL would be the first member of a new class of analgesic drugs for fibromyalgia and the first new drug available for treating fibromyalgia in more than 15 years. Fibromyalgia affects more than 10 million adults in the U.S., most of whom are women.</li><li>In September 2024, at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS 2024), the Company announced data highlighting the proprietary formulation technology and pharmacokinetic properties of TNX-102 SL, including composition and methods patents based on the proprietary eutectic<sup>1</sup> formulation of TNX-102 SL that are expected to provide market exclusivity until at least 2034 in the U.S., EU, Japan, China and other jurisdictions. The eutectic protects cyclobenzaprine HCl from interacting with the basifying agent that is also part of the formulation and required for efficient transmucosal absorption. The formulation of TNX-102 SL was designed specifically for sublingual administration and transmucosal absorption for bedtime dosing to target disturbed sleep, improve pain and other fibromyalgia symptoms, while reducing the risk of daytime somnolence.</li><li>In August 2024, at both the DoD’s 2024 Military Health System Research Symposium (MHSRS), and at the International Association for the Study of Pain’s (IASP’s) 2024 World Congress on Pain, Tonix announced additional data and analyses of TNX-102 SL for the management of fibromyalgia. TNX-102 SL had met the pre-specified primary endpoint in the Phase 3 RESILIENT study, significantly reducing daily pain compared to placebo (p-value=0.00005) in participants with fibromyalgia while demonstrating broad syndromal benefits with statistically significant improvement in all six pre-specified key secondary endpoints, including those related to improving sleep quality, reducing fatigue, and improving patient global ratings and overall fibromyalgia symptoms and function. TNX-102 SL was well tolerated with an adverse event profile comparable to prior studies and no new safety signals were observed.<br/></li><li>In July 2024, Tonix noted that, based on the new definition of Long COVID by the U.S. National Academies of Sciences, Engineering and Medicine (NASEM), fibromyalgia is a ‘diagnosable condition’ in people suffering from Long COVID. The Company believes that diagnosing fibromyalgia in Long COVID patients will increase the potential market for TNX-102 SL following approval as compared to market estimates from before the COVID-19 pandemic.<br/></li></ul> <p><em>TNX-102 SL for the treatment of acute stress reaction (ASR) and acute stress disorder (ASD), and prophylaxis against development of posttraumatic stress disorder (PTSD)</em></p> <ul type=\"disc\"><li>In August 2024 at the DoD’s MHSRS conference, the Company presented clinical data and rationale supporting the potential for TNX-102 SL to be studied for the treatment of ASR and prevention of PTSD. Prior studies showed that treatment with TNX-102 SL showed effects on sleep and PTSD symptoms in PTSD patients at two and four weeks<sup>1</sup>. This supportive data on the effects of TNX-102 SL on reducing PTSD symptoms suggest early intervention immediately after trauma using TNX-102 SL has the potential to reduce ASR/ASD symptoms which are similar to those of PTSD<sup>2</sup><sup>,</sup><sup>3</sup>. Data from these trials support testing of TNX-102 SL within 24 hours of index trauma for effects on ASR symptoms and the subsequent incidence of PTSD.</li><li>The DoD-funded Optimizing Acute Stress Reaction Interventions (OASIS) trial will be conducted by the University of North Carolina under an investigator-initiated investigational new drug (IND) application. The OASIS trial will examine the safety and efficacy of TNX-102 SL to reduce adverse posttraumatic neuropsychiatric sequelae among patients in the emergency department (ED) after a motor vehicle collision. Fourteen days of bedtime TNX-102 SL will be dosed and tested in the immediate aftermath of motor vehicle collision. The study will test the potential for TNX-102 SL to target trauma-related sleep disturbance and its ability to facilitate recovery from ASR and to prevent PTSD. The results may ultimately provide military personnel with a new treatment option that, when administered in the early aftermath of a traumatic event to individuals with ASR symptoms, improves warfighter function.</li></ul> <p><em>TNX-1300 (recombinant double mutant cocaine esterase): biologic for life-threatening cocaine intoxication</em></p> <ul type=\"disc\"><li>Tonix announced the first patient in the Phase 2 CATALYST study of TNX-1300 for the treatment of cocaine intoxication was enrolled in August 2024. CATALYST is a Phase 2 single-blind, placebo-controlled, proof-of-concept study in patients presenting to the emergency department. Topline results are expected in the first half of 2025.<br/></li><li>The National Institutes of Health (NIH)’s National Institute of Drug Abuse (NIDA) previously awarded Tonix a Cooperative Agreement grant for approximately $5 million from to support development of TNX-1300.<br/></li><li>TNX-1300 has been granted Breakthrough Therapy designation by the FDA.</li></ul> <p><em><u>Infectious Disease Pipeline</u></em></p> <p><em>TNX-801 (recombinant horsepox virus, live vaccine): potential vaccine to protect against mpox disease and smallpox.</em></p> <ul type=\"disc\"><li>In September 2024, at the DoD’s MHSRS conference and in October 2024 at the World Vaccine Congress in Barcelona, Spain, Tonix presented new data on potential mpox vaccine, TNX-801, demonstrating tolerability and no evidence of spreading to blood or tissues, even at high doses, in immunocompromised animals. TNX-801 is an attenuated live-virus vaccine based on synthesized horsepox that has been shown to provide single-dose immune protection against a monkeypox challenge. After a single-dose vaccination, TNX-801 prevented clinical disease and lesions, and also decreased shedding in the mouth and lungs of non-human primates after a lethal challenge with Clade Ia monkeypox. These findings are consistent with TNX-801 inducing mucosal immunity and suggest TNX-801 has the ability to block forward transmission.</li><li>In August 2024, the WHO determined that the upsurge of mpox in a growing number of countries in Africa constitutes a public health emergency of international concern (PHEIC), the second such declaration in the past two years in response to transmission of the virus. Mpox cases of the new clade 1b mpox have since also been detected in Sweden, Thailand, Singapore, India, Germany and England.</li><li>In September 2024, the Company announced that the WHO’s preferred TPP aligns with the characteristics of TNX-801. Key elements of the WHO draft TPP include single-dose, durable protection, administration without special equipment, and stability at ambient temperature. Other potential beneficial characteristics include the ability to limit forward transmission, use in case-contact vaccination strategies and suitability for use in immunocompromised individuals.<br/></li></ul> <p>Footnotes:</p> <ol><li><em>The TNX-102 SL eutectic is a composition of matter based on co-penetration of cyclobenzaprine HCl and mannitol crystals and protected by 5 issued U.S patents: Nos. 9,636,408; 9,956,188; 10,117,936; 10,864,175; 11,839,594; 9,918,948; 11,826,321.</em><br/></li><li><em>Sullivan GM, et al. Randomized clinical trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related PTSD and the role of sleep quality in treatment response. Psychiatry Res. 2021 Jul;301:113974.</em><br/></li><li><em>Parmenter ME, et al. A phase 3, randomized, placebo-controlled, trial to evaluate the efficacy and safety of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related posttraumatic stress disorder. Psychiatry Res. 2024 (In Press). https://doi.org/10.1016/j.psychres.2024.115764</em><br/></li></ol> <p><strong>Corporate and Partnerships – Recent Highlights</strong></p> <ul type=\"disc\"><li>In November 2024, the Company announced that it has entered into a sponsored research agreement with the Kenya Medical Research Institute (KEMRI) to design, plan and seek regulatory approval for a Phase I clinical study in Kenya to test the safety, tolerability, and immunogenicity of TNX-801 (horsepox, live virus) as a vaccine to prevent mpox and smallpox. Tonix is expected be the sponsor and KEMRI is expected to lead the execution of the proposed clinical trial.<br/><br/></li><li>In October 2024, the Company announced it entered into an artificial intelligence and machine learning drug discovery collaboration with X-Chem, Inc., a leader in small molecule drug discovery, to accelerate the development of small molecules as orally available host-targeted broad-spectrum medical countermeasures. Tonix’s TNX-4200 antiviral program focuses on the development of oral CD45 phosphatase inhibitors, with broad-spectrum activity against a range of viral families.<br/><br/></li><li>In September 2024, Tonix announced the appointment of Thomas Englese as its new Executive Vice President, Commercial Operations. Mr. Englese brings significant leadership to Tonix across several functions, including commercial operations, sales and marketing, and launching and managing major brands through all stages of commercialization.   <br/><br/></li><li>In August 2024, the Company announced a collaboration with Bilthoven Biologics (Bbio) to develop GMP manufacturing processes for TNX-801 as a potential mpox vaccine. Bbio is part of the world’s largest vaccine manufacturer, the Cyrus Poonawalla Group, which also includes the Serum Institute of India.   <br/><br/></li><li>In July 2024, Tonix announced it had been awarded a DoD contract with a potential for up to $34 million over five years by DoD’s Defense Threat Reduction Agency (DTRA). The objective of the contract is to develop small molecule broad-spectrum antiviral agents for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix’s program will focus on optimization and development of its TNX-4200 program, to develop an orally available CD45 antagonist, with broad-spectrum efficacy against a range of viral families through preclinical evaluation. The program is expected to establish physicochemical properties, pharmacokinetics, and safety attributes to support an IIND submission and to fund a first-in-human Phase 1 clinical study.<br/></li></ul> <p><strong>Marketed Products – Recent Highlights</strong></p> <ul type=\"disc\"><li>In September 2024, Tonix announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 12,097,183 to the Company, claiming use of a pre-filled autoinjector comprising a composition of Zembrace® SymTouch® for treating migraines via subcutaneous administration. This patent, excluding possible patent term extensions, is expected to fortify protection and market exclusivity into 2036.</li><li>Tonix announced that the USPTO issued U.S. Patent No. 12,090,139 to the Company, claiming a pharmaceutical composition, a method of treating migraine via intranasal administration, and an intranasal delivery system for Tosymra®. This patent is expected to fortify protection and market exclusivity into 2030.</li></ul> <p>Tonix Medicines launched a national educational campaign focusing on the link between migraine, gastroparesis, and the need for non-oral acute migraine therapies. Tonix Medicines is the only manufacturer with both a branded injectable and nasal spray indicated for the acute treatment of migraine with or without aura in adults.</p> <p><strong>Financial - Recent Highlight</strong></p> <p>As of September 30, 2024, Tonix had approximately $28.2 million of cash and cash equivalents, compared to approximately $24.9 million as of December 31, 2023. Additionally, Tonix had inventory totaling approximately $7.9 million as of September 30, 2024. Net cash used in operations was approximately $46.3 million for the nine months ended September 30, 2024, compared to approximately $79.7 million for the same period in 2023. Cash used in investing activities for the nine months ended September 30, 2024 was approximately $117,000 compared to $28.6 million for the same period in 2023.</p> <p>In July 2024, Tonix received net proceeds of approximately $3.5 million in a securities offering with certain institutional and retail investors. Additionally, during the three months ended September 30, 2024, Tonix sold approximately 134.5 million shares of common stock under the 2024 ATM Sales Agreement for net proceeds of approximately $41.8 million.</p> <p><u>Third Quarter 2024 Financial Results</u></p> <p>Net product revenue for the third quarter 2024 was approximately $2.8 million. Net product revenue consisted of combined net sales of Zembrace® SymTouch® and Tosymra®, which were acquired from Upsher-Smith Laboratories, LLC on June 30, 2023. Cost of sales for the third quarter 2024 was approximately $1.6 million.</p> <p>During the three months ended September 30, 2024, Tonix received its first payment from DTRA as part of its previously announced award from DTRA for up to $34 million over five years.</p> <p>Research and development expenses for the third quarter 2024 were approximately $9.1 million, compared to $21.0 million for the same period in 2023. This decrease is predominantly due to lower clinical, non-clinical and manufacturing expenses aligned with the Company’s capital efficient strategy.</p> <p>Selling, general and administrative expenses for the third quarter 2024 were approximately $7.7 million, compared to $8.7 million for the same period in 2023. The decrease was primarily due to lower employee-related expenses, transactional services and sales and marketing expenses partially offset by an increase in professional fees.</p> <p>Net loss available to common stockholders was approximately $14.2 million, or $0.23 per share, basic and diluted, for the third quarter 2024, compared to net loss available to common stockholders of $28.0 million, or $38.63 per share, basic and diluted, for the same period in 2023. The basic and diluted weighted average common shares outstanding for the third quarter 2024 was 62,122,283 compared to 724,190 shares for the same period in 2023.</p> <p><strong>Tonix Pharmaceuticals Holding Corp.</strong><sup><strong>*</strong></sup><br/>Tonix is a fully-integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. We expect an FDA decision on the acceptance of the NDA for review and a PDUFA date in December and if accepted, a decision on NDA approval in 2025. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation and its development is supported by a grant from the U.S. National Institute of Drug Abuse and Addiction. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease, including TNX-2900 for Prader-Willi syndrome, and infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, MD. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.</p> <p>* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.</p> <p>Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.</p> <p>This press release and further information about Tonix can be found at <u>www.tonixpharma.com</u>.</p> <p><strong>Forward Looking Statements</strong></p> <p>Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.</p> <table><tr><td colspan=\"18\"><strong>TONIX PHARMACEUTICALS HOLDING CORP.</strong> <br/><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</strong><br/><strong>(In Thousands, Except Share and Per Share Amounts)</strong><br/><strong>(unaudited)</strong><strong><br/></strong></td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td colspan=\"6\"><strong>Three Months Ended</strong><br/><strong>September 30,</strong><strong><br/></strong></td><td> </td><td> </td><td colspan=\"6\"><strong>Nine Months Ended</strong><br/><strong>September 30,</strong><strong><br/></strong></td><td> </td></tr><tr><td> </td><td> </td><td> </td><td colspan=\"2\"><strong>2024</strong><strong><br/></strong></td><td> </td><td> </td><td colspan=\"2\"><strong>2023</strong><strong><br/></strong></td><td> </td><td> </td><td colspan=\"2\"><strong>2024</strong><strong><br/></strong></td><td> </td><td> </td><td colspan=\"2\"><strong>2023</strong><strong><br/></strong></td><td> </td></tr><tr><td>REVENUE:</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Product revenue, net</td><td> </td><td> </td><td>$</td><td>2,822</td><td> </td><td> </td><td>$</td><td>3,989</td><td> </td><td> </td><td>$</td><td>7,512</td><td> </td><td> </td><td>$</td><td>3,989</td><td> </td></tr><tr><td>COSTS AND EXPENSES:</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Cost of revenue</td><td> </td><td> </td><td> </td><td>1,555</td><td> </td><td> </td><td> </td><td>2,374</td><td> </td><td> </td><td> </td><td>6,582</td><td> </td><td> </td><td> </td><td>2,374</td><td> </td></tr><tr><td>Research and development</td><td> </td><td> </td><td> </td><td>9,114</td><td> </td><td> </td><td> </td><td>21,050</td><td> </td><td> </td><td> </td><td>31,675</td><td> </td><td> </td><td> </td><td>69,535</td><td> </td></tr><tr><td>Selling, general and administrative</td><td> </td><td> </td><td> </td><td>7,707</td><td> </td><td> </td><td> </td><td>8,712</td><td> </td><td> </td><td> </td><td>24,519</td><td> </td><td> </td><td> </td><td>23,131</td><td> </td></tr><tr><td>Asset impairment charges</td><td> </td><td> </td><td> </td><td>—</td><td> </td><td> </td><td> </td><td>—</td><td> </td><td> </td><td> </td><td>58,957</td><td> </td><td> </td><td> </td><td>—</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td>18,376</td><td> </td><td> </td><td> </td><td>32,136</td><td> </td><td> </td><td> </td><td>121,733</td><td> </td><td> </td><td> </td><td>95,040</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Operating loss</td><td> </td><td> </td><td> </td><td>(15,554</td><td>)</td><td> </td><td> </td><td>(28,147</td><td>)</td><td> </td><td> </td><td>(114,221</td><td>)</td><td> </td><td> </td><td>(91,051</td><td>)</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Grant income</td><td> </td><td> </td><td> </td><td>1,668</td><td> </td><td> </td><td> </td><td>—</td><td> </td><td> </td><td> </td><td>1,668</td><td> </td><td> </td><td> </td><td>—</td><td> </td></tr><tr><td>Gain on change in fair value of warrant liabilities</td><td> </td><td> </td><td> </td><td>—</td><td> </td><td> </td><td> </td><td>—</td><td> </td><td> </td><td> </td><td>6,150</td><td> </td><td> </td><td> </td><td>—</td><td> </td></tr><tr><td>Other (expense) income, net</td><td> </td><td> </td><td> </td><td>(327</td><td>)</td><td> </td><td> </td><td>172</td><td> </td><td> </td><td> </td><td>(1,525</td><td>)</td><td> </td><td> </td><td>1,715</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Net loss available to common stockholders</td><td> </td><td> </td><td>$</td><td>(14,213</td><td>)</td><td> </td><td>$</td><td>(27,975</td><td>)</td><td> </td><td>$</td><td>(107,928</td><td>)</td><td> </td><td>$</td><td>(89,336</td><td>)</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Net loss per common share, basic and diluted</td><td> </td><td> </td><td>$</td><td>(0.23</td><td>)</td><td> </td><td>$</td><td>(38.63</td><td>)</td><td> </td><td>$</td><td>(4.66</td><td>)</td><td> </td><td>$</td><td>(143.47</td><td>)</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Weighted average common shares outstanding, basic and diluted</td><td> </td><td> </td><td> </td><td>62,122,283</td><td> </td><td> </td><td> </td><td>724,190</td><td> </td><td> </td><td> </td><td>23,136,172</td><td> </td><td> </td><td> </td><td>622,684</td><td> </td></tr><tr><td colspan=\"18\"> </td></tr></table> <table><tr><td colspan=\"6\"><strong>TONIX PHARMACEUTICALS HOLDING CORP.</strong><br/><strong>CONDENSED CONSOLIDATED BALANCE SHEETS</strong><br/><strong> (In Thousands)</strong><br/><strong>(Unaudited)</strong></td></tr><tr><td colspan=\"6\"> </td></tr><tr><td><strong> </strong></td><td colspan=\"2\"><strong>September 30, 2024</strong><strong><br/></strong></td><td> </td><td colspan=\"2\"><strong>December 31, 2023<sup><strong>1</strong></sup></strong><strong><br/></strong></td></tr><tr><td><strong>Assets</strong></td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Cash and cash equivalents</td><td>$   28,233</td><td> </td><td> </td><td>$   24,948</td><td> </td></tr><tr><td>Accounts Receivable, net</td><td>4,013</td><td> </td><td> </td><td>-</td><td> </td></tr><tr><td>Inventory</td><td>7,931</td><td> </td><td> </td><td>13,639</td><td> </td></tr><tr><td>Prepaid expenses and other</td><td>10,366</td><td> </td><td> </td><td>9,181</td><td> </td></tr><tr><td>Total current assets</td><td>50,543</td><td> </td><td> </td><td>47,768</td><td> </td></tr><tr><td>Other non-current assets</td><td>44,446</td><td> </td><td> </td><td>106,689</td><td> </td></tr><tr><td>Total assets</td><td>$   94,989</td><td> </td><td> </td><td>$   154,457</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><strong>Liabilities and stockholders' equity</strong></td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Total liabilities</td><td>$   20,778</td><td> </td><td> </td><td>$   48,932</td><td> </td></tr><tr><td>Stockholders' equity</td><td>74,211</td><td> </td><td> </td><td>105,525</td><td> </td></tr><tr><td>Total liabilities and stockholders' equity</td><td>$   94,989</td><td> </td><td> </td><td>$   154,457</td><td> </td></tr><tr><td colspan=\"6\"> </td></tr><tr><td colspan=\"6\"><sup>1</sup>The condensed consolidated balance sheet for the year ended December 31, 2023 has been derived from the audited financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.</td></tr><tr><td colspan=\"6\"> </td></tr></table> <p><strong>Investor Contact</strong></p> <p>Jessica Morris<br/>Tonix Pharmaceuticals<br/><u>investor.relations@tonixpharma.com</u> <br/>(862) 904-8182</p> <p>Peter Vozzo<br/>ICR Healthcare<br/><u>peter.vozzo@westwicke.com</u> <br/>(443) 213-0505</p> <p><strong>Media Contact</strong></p> <p>Ray Jordan<br/>Putnam Insights<br/>ray@putnaminsights.com<br/>(949) 245-5432</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MDk5YmE2ZGItNTRmMy00Y2JiLWExOTItNDIxODhkZjhjMjc4LTEwMjI2ODU=/tiny/Tonix-Pharmaceuticals-Holding-.png\"/></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time\">2024-12-17 00:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><em>Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studies</em></p> <p><em>Granted Fast Track Designation by FDA in July 2024 for TNX-102 SL, a centrally-acting, non-opioid analgesic; Fibromyalgia is a common chronic pain condition that affects mostly women</em></p> <p><em>Expect FDA decision in December 2024 on TNX-102 SL NDA acceptance for review and 2025 PDUFA date; If FDA-approved in 2025, TNX-102 SL would be the first new drug for fibromyalgia in more than 15 years</em></p> <p><em>Presented new data on potential mpox vaccine, TNX-801, in September and October 2024, demonstrating tolerability in immunocompromised animals; Previously reported studies showed a single-dose provided immune protection against a monkeypox challenge </em></p> <p><em>Awarded U.S. Department of Defense (DoD) contract for up to $34 million over five years in July 2024 to develop a broad-spectrum antiviral drug; Received first payment from DTRA</em></p> <p>CHATHAM, N.J., Dec.  16, 2024  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced financial results for the third quarter ended September 30, 2024, and provided an overview of recent operational highlights.</p> <p>“With our recent NDA submission to the U.S. Food and Drug Administration (FDA), Tonix is excited about the potential of TNX-102 SL to become the first new drug treatment option in more than 15 years for the roughly 10 million adults in the U.S. suffering from fibromyalgia,” said Seth Lederman, M.D., Chief Executive Officer of Tonix. “FDA awarded TNX-102 SL Fast Track designation in the third quarter of 2024, which is intended to expedite FDA review of important new drugs to fill unmet needs for serious conditions. We look forward to next steps with FDA. If the NDA filing is accepted in December, we expect a decision on the marketing approval of TNX-102 SL for fibromyalgia in 2025.”</p> <p>Dr. Lederman continued, “As we continue to advance key pipeline products through a capital efficient strategy, we are excited to have announced collaborations with world-class institutions to advance the development of TNX-801, a potential mpox vaccine whose single-dose administration and other characteristics align closely with The World Health Organization’s preferred target product profile (TPP) criteria for mpox vaccines. The World Health Organization (WHO) previously announced the growing number of mpox cases constitutes a public health emergency of international concern (PHEIC), with clade 1b mpox strains now detected in 16 countries in Africa as well as in Sweden, Thailand, Singapore, India, England and Germany.”</p> <p><strong>Key Product Candidates* -- Recent Highlights </strong></p> <p><em><u>Central Nervous System (CNS) Pipeline</u></em></p> <p><em>TNX-102 SL (cyclobenzaprine HCl sublingual tablets): 5.6 mg, once-daily at bedtime small molecule for the management of fibromyalgia (FM) – a centrally-acting, non-opioid analgesic.</em></p> <ul type=\"disc\"><li>In October 2024, Tonix announced submission of the TNX-102 SL New Drug Application (NDA) for fibromyalgia to the FDA. The submission was based upon two Phase 3 studies of TNX-102 SL in fibromyalgia that showed statically significant reduction in the chronic, widespread pain associated with fibromyalgia. If approved by the FDA, TNX-102 SL would be the first member of a new class of analgesic drugs for fibromyalgia and the first new drug available for treating fibromyalgia in more than 15 years. Fibromyalgia affects more than 10 million adults in the U.S., most of whom are women.</li><li>In September 2024, at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS 2024), the Company announced data highlighting the proprietary formulation technology and pharmacokinetic properties of TNX-102 SL, including composition and methods patents based on the proprietary eutectic<sup>1</sup> formulation of TNX-102 SL that are expected to provide market exclusivity until at least 2034 in the U.S., EU, Japan, China and other jurisdictions. The eutectic protects cyclobenzaprine HCl from interacting with the basifying agent that is also part of the formulation and required for efficient transmucosal absorption. The formulation of TNX-102 SL was designed specifically for sublingual administration and transmucosal absorption for bedtime dosing to target disturbed sleep, improve pain and other fibromyalgia symptoms, while reducing the risk of daytime somnolence.</li><li>In August 2024, at both the DoD’s 2024 Military Health System Research Symposium (MHSRS), and at the International Association for the Study of Pain’s (IASP’s) 2024 World Congress on Pain, Tonix announced additional data and analyses of TNX-102 SL for the management of fibromyalgia. TNX-102 SL had met the pre-specified primary endpoint in the Phase 3 RESILIENT study, significantly reducing daily pain compared to placebo (p-value=0.00005) in participants with fibromyalgia while demonstrating broad syndromal benefits with statistically significant improvement in all six pre-specified key secondary endpoints, including those related to improving sleep quality, reducing fatigue, and improving patient global ratings and overall fibromyalgia symptoms and function. TNX-102 SL was well tolerated with an adverse event profile comparable to prior studies and no new safety signals were observed.<br/></li><li>In July 2024, Tonix noted that, based on the new definition of Long COVID by the U.S. National Academies of Sciences, Engineering and Medicine (NASEM), fibromyalgia is a ‘diagnosable condition’ in people suffering from Long COVID. The Company believes that diagnosing fibromyalgia in Long COVID patients will increase the potential market for TNX-102 SL following approval as compared to market estimates from before the COVID-19 pandemic.<br/></li></ul> <p><em>TNX-102 SL for the treatment of acute stress reaction (ASR) and acute stress disorder (ASD), and prophylaxis against development of posttraumatic stress disorder (PTSD)</em></p> <ul type=\"disc\"><li>In August 2024 at the DoD’s MHSRS conference, the Company presented clinical data and rationale supporting the potential for TNX-102 SL to be studied for the treatment of ASR and prevention of PTSD. Prior studies showed that treatment with TNX-102 SL showed effects on sleep and PTSD symptoms in PTSD patients at two and four weeks<sup>1</sup>. This supportive data on the effects of TNX-102 SL on reducing PTSD symptoms suggest early intervention immediately after trauma using TNX-102 SL has the potential to reduce ASR/ASD symptoms which are similar to those of PTSD<sup>2</sup><sup>,</sup><sup>3</sup>. Data from these trials support testing of TNX-102 SL within 24 hours of index trauma for effects on ASR symptoms and the subsequent incidence of PTSD.</li><li>The DoD-funded Optimizing Acute Stress Reaction Interventions (OASIS) trial will be conducted by the University of North Carolina under an investigator-initiated investigational new drug (IND) application. The OASIS trial will examine the safety and efficacy of TNX-102 SL to reduce adverse posttraumatic neuropsychiatric sequelae among patients in the emergency department (ED) after a motor vehicle collision. Fourteen days of bedtime TNX-102 SL will be dosed and tested in the immediate aftermath of motor vehicle collision. The study will test the potential for TNX-102 SL to target trauma-related sleep disturbance and its ability to facilitate recovery from ASR and to prevent PTSD. The results may ultimately provide military personnel with a new treatment option that, when administered in the early aftermath of a traumatic event to individuals with ASR symptoms, improves warfighter function.</li></ul> <p><em>TNX-1300 (recombinant double mutant cocaine esterase): biologic for life-threatening cocaine intoxication</em></p> <ul type=\"disc\"><li>Tonix announced the first patient in the Phase 2 CATALYST study of TNX-1300 for the treatment of cocaine intoxication was enrolled in August 2024. CATALYST is a Phase 2 single-blind, placebo-controlled, proof-of-concept study in patients presenting to the emergency department. Topline results are expected in the first half of 2025.<br/></li><li>The National Institutes of Health (NIH)’s National Institute of Drug Abuse (NIDA) previously awarded Tonix a Cooperative Agreement grant for approximately $5 million from to support development of TNX-1300.<br/></li><li>TNX-1300 has been granted Breakthrough Therapy designation by the FDA.</li></ul> <p><em><u>Infectious Disease Pipeline</u></em></p> <p><em>TNX-801 (recombinant horsepox virus, live vaccine): potential vaccine to protect against mpox disease and smallpox.</em></p> <ul type=\"disc\"><li>In September 2024, at the DoD’s MHSRS conference and in October 2024 at the World Vaccine Congress in Barcelona, Spain, Tonix presented new data on potential mpox vaccine, TNX-801, demonstrating tolerability and no evidence of spreading to blood or tissues, even at high doses, in immunocompromised animals. TNX-801 is an attenuated live-virus vaccine based on synthesized horsepox that has been shown to provide single-dose immune protection against a monkeypox challenge. After a single-dose vaccination, TNX-801 prevented clinical disease and lesions, and also decreased shedding in the mouth and lungs of non-human primates after a lethal challenge with Clade Ia monkeypox. These findings are consistent with TNX-801 inducing mucosal immunity and suggest TNX-801 has the ability to block forward transmission.</li><li>In August 2024, the WHO determined that the upsurge of mpox in a growing number of countries in Africa constitutes a public health emergency of international concern (PHEIC), the second such declaration in the past two years in response to transmission of the virus. Mpox cases of the new clade 1b mpox have since also been detected in Sweden, Thailand, Singapore, India, Germany and England.</li><li>In September 2024, the Company announced that the WHO’s preferred TPP aligns with the characteristics of TNX-801. Key elements of the WHO draft TPP include single-dose, durable protection, administration without special equipment, and stability at ambient temperature. Other potential beneficial characteristics include the ability to limit forward transmission, use in case-contact vaccination strategies and suitability for use in immunocompromised individuals.<br/></li></ul> <p>Footnotes:</p> <ol><li><em>The TNX-102 SL eutectic is a composition of matter based on co-penetration of cyclobenzaprine HCl and mannitol crystals and protected by 5 issued U.S patents: Nos. 9,636,408; 9,956,188; 10,117,936; 10,864,175; 11,839,594; 9,918,948; 11,826,321.</em><br/></li><li><em>Sullivan GM, et al. Randomized clinical trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related PTSD and the role of sleep quality in treatment response. Psychiatry Res. 2021 Jul;301:113974.</em><br/></li><li><em>Parmenter ME, et al. A phase 3, randomized, placebo-controlled, trial to evaluate the efficacy and safety of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related posttraumatic stress disorder. Psychiatry Res. 2024 (In Press). https://doi.org/10.1016/j.psychres.2024.115764</em><br/></li></ol> <p><strong>Corporate and Partnerships – Recent Highlights</strong></p> <ul type=\"disc\"><li>In November 2024, the Company announced that it has entered into a sponsored research agreement with the Kenya Medical Research Institute (KEMRI) to design, plan and seek regulatory approval for a Phase I clinical study in Kenya to test the safety, tolerability, and immunogenicity of TNX-801 (horsepox, live virus) as a vaccine to prevent mpox and smallpox. Tonix is expected be the sponsor and KEMRI is expected to lead the execution of the proposed clinical trial.<br/><br/></li><li>In October 2024, the Company announced it entered into an artificial intelligence and machine learning drug discovery collaboration with X-Chem, Inc., a leader in small molecule drug discovery, to accelerate the development of small molecules as orally available host-targeted broad-spectrum medical countermeasures. Tonix’s TNX-4200 antiviral program focuses on the development of oral CD45 phosphatase inhibitors, with broad-spectrum activity against a range of viral families.<br/><br/></li><li>In September 2024, Tonix announced the appointment of Thomas Englese as its new Executive Vice President, Commercial Operations. Mr. Englese brings significant leadership to Tonix across several functions, including commercial operations, sales and marketing, and launching and managing major brands through all stages of commercialization.   <br/><br/></li><li>In August 2024, the Company announced a collaboration with Bilthoven Biologics (Bbio) to develop GMP manufacturing processes for TNX-801 as a potential mpox vaccine. Bbio is part of the world’s largest vaccine manufacturer, the Cyrus Poonawalla Group, which also includes the Serum Institute of India.   <br/><br/></li><li>In July 2024, Tonix announced it had been awarded a DoD contract with a potential for up to $34 million over five years by DoD’s Defense Threat Reduction Agency (DTRA). The objective of the contract is to develop small molecule broad-spectrum antiviral agents for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix’s program will focus on optimization and development of its TNX-4200 program, to develop an orally available CD45 antagonist, with broad-spectrum efficacy against a range of viral families through preclinical evaluation. The program is expected to establish physicochemical properties, pharmacokinetics, and safety attributes to support an IIND submission and to fund a first-in-human Phase 1 clinical study.<br/></li></ul> <p><strong>Marketed Products – Recent Highlights</strong></p> <ul type=\"disc\"><li>In September 2024, Tonix announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 12,097,183 to the Company, claiming use of a pre-filled autoinjector comprising a composition of Zembrace® SymTouch® for treating migraines via subcutaneous administration. This patent, excluding possible patent term extensions, is expected to fortify protection and market exclusivity into 2036.</li><li>Tonix announced that the USPTO issued U.S. Patent No. 12,090,139 to the Company, claiming a pharmaceutical composition, a method of treating migraine via intranasal administration, and an intranasal delivery system for Tosymra®. This patent is expected to fortify protection and market exclusivity into 2030.</li></ul> <p>Tonix Medicines launched a national educational campaign focusing on the link between migraine, gastroparesis, and the need for non-oral acute migraine therapies. Tonix Medicines is the only manufacturer with both a branded injectable and nasal spray indicated for the acute treatment of migraine with or without aura in adults.</p> <p><strong>Financial - Recent Highlight</strong></p> <p>As of September 30, 2024, Tonix had approximately $28.2 million of cash and cash equivalents, compared to approximately $24.9 million as of December 31, 2023. Additionally, Tonix had inventory totaling approximately $7.9 million as of September 30, 2024. Net cash used in operations was approximately $46.3 million for the nine months ended September 30, 2024, compared to approximately $79.7 million for the same period in 2023. Cash used in investing activities for the nine months ended September 30, 2024 was approximately $117,000 compared to $28.6 million for the same period in 2023.</p> <p>In July 2024, Tonix received net proceeds of approximately $3.5 million in a securities offering with certain institutional and retail investors. Additionally, during the three months ended September 30, 2024, Tonix sold approximately 134.5 million shares of common stock under the 2024 ATM Sales Agreement for net proceeds of approximately $41.8 million.</p> <p><u>Third Quarter 2024 Financial Results</u></p> <p>Net product revenue for the third quarter 2024 was approximately $2.8 million. Net product revenue consisted of combined net sales of Zembrace® SymTouch® and Tosymra®, which were acquired from Upsher-Smith Laboratories, LLC on June 30, 2023. Cost of sales for the third quarter 2024 was approximately $1.6 million.</p> <p>During the three months ended September 30, 2024, Tonix received its first payment from DTRA as part of its previously announced award from DTRA for up to $34 million over five years.</p> <p>Research and development expenses for the third quarter 2024 were approximately $9.1 million, compared to $21.0 million for the same period in 2023. This decrease is predominantly due to lower clinical, non-clinical and manufacturing expenses aligned with the Company’s capital efficient strategy.</p> <p>Selling, general and administrative expenses for the third quarter 2024 were approximately $7.7 million, compared to $8.7 million for the same period in 2023. The decrease was primarily due to lower employee-related expenses, transactional services and sales and marketing expenses partially offset by an increase in professional fees.</p> <p>Net loss available to common stockholders was approximately $14.2 million, or $0.23 per share, basic and diluted, for the third quarter 2024, compared to net loss available to common stockholders of $28.0 million, or $38.63 per share, basic and diluted, for the same period in 2023. The basic and diluted weighted average common shares outstanding for the third quarter 2024 was 62,122,283 compared to 724,190 shares for the same period in 2023.</p> <p><strong>Tonix Pharmaceuticals Holding Corp.</strong><sup><strong>*</strong></sup><br/>Tonix is a fully-integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. We expect an FDA decision on the acceptance of the NDA for review and a PDUFA date in December and if accepted, a decision on NDA approval in 2025. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation and its development is supported by a grant from the U.S. National Institute of Drug Abuse and Addiction. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease, including TNX-2900 for Prader-Willi syndrome, and infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, MD. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.</p> <p>* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.</p> <p>Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.</p> <p>This press release and further information about Tonix can be found at <u>www.tonixpharma.com</u>.</p> <p><strong>Forward Looking Statements</strong></p> <p>Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.</p> <table><tr><td colspan=\"18\"><strong>TONIX PHARMACEUTICALS HOLDING CORP.</strong> <br/><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</strong><br/><strong>(In Thousands, Except Share and Per Share Amounts)</strong><br/><strong>(unaudited)</strong><strong><br/></strong></td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td colspan=\"6\"><strong>Three Months Ended</strong><br/><strong>September 30,</strong><strong><br/></strong></td><td> </td><td> </td><td colspan=\"6\"><strong>Nine Months Ended</strong><br/><strong>September 30,</strong><strong><br/></strong></td><td> </td></tr><tr><td> </td><td> </td><td> </td><td colspan=\"2\"><strong>2024</strong><strong><br/></strong></td><td> </td><td> </td><td colspan=\"2\"><strong>2023</strong><strong><br/></strong></td><td> </td><td> </td><td colspan=\"2\"><strong>2024</strong><strong><br/></strong></td><td> </td><td> </td><td colspan=\"2\"><strong>2023</strong><strong><br/></strong></td><td> </td></tr><tr><td>REVENUE:</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Product revenue, net</td><td> </td><td> </td><td>$</td><td>2,822</td><td> </td><td> </td><td>$</td><td>3,989</td><td> </td><td> </td><td>$</td><td>7,512</td><td> </td><td> </td><td>$</td><td>3,989</td><td> </td></tr><tr><td>COSTS AND EXPENSES:</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Cost of revenue</td><td> </td><td> </td><td> </td><td>1,555</td><td> </td><td> </td><td> </td><td>2,374</td><td> </td><td> </td><td> </td><td>6,582</td><td> </td><td> </td><td> </td><td>2,374</td><td> </td></tr><tr><td>Research and development</td><td> </td><td> </td><td> </td><td>9,114</td><td> </td><td> </td><td> </td><td>21,050</td><td> </td><td> </td><td> </td><td>31,675</td><td> </td><td> </td><td> </td><td>69,535</td><td> </td></tr><tr><td>Selling, general and administrative</td><td> </td><td> </td><td> </td><td>7,707</td><td> </td><td> </td><td> </td><td>8,712</td><td> </td><td> </td><td> </td><td>24,519</td><td> </td><td> </td><td> </td><td>23,131</td><td> </td></tr><tr><td>Asset impairment charges</td><td> </td><td> </td><td> </td><td>—</td><td> </td><td> </td><td> </td><td>—</td><td> </td><td> </td><td> </td><td>58,957</td><td> </td><td> </td><td> </td><td>—</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td>18,376</td><td> </td><td> </td><td> </td><td>32,136</td><td> </td><td> </td><td> </td><td>121,733</td><td> </td><td> </td><td> </td><td>95,040</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Operating loss</td><td> </td><td> </td><td> </td><td>(15,554</td><td>)</td><td> </td><td> </td><td>(28,147</td><td>)</td><td> </td><td> </td><td>(114,221</td><td>)</td><td> </td><td> </td><td>(91,051</td><td>)</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Grant income</td><td> </td><td> </td><td> </td><td>1,668</td><td> </td><td> </td><td> </td><td>—</td><td> </td><td> </td><td> </td><td>1,668</td><td> </td><td> </td><td> </td><td>—</td><td> </td></tr><tr><td>Gain on change in fair value of warrant liabilities</td><td> </td><td> </td><td> </td><td>—</td><td> </td><td> </td><td> </td><td>—</td><td> </td><td> </td><td> </td><td>6,150</td><td> </td><td> </td><td> </td><td>—</td><td> </td></tr><tr><td>Other (expense) income, net</td><td> </td><td> </td><td> </td><td>(327</td><td>)</td><td> </td><td> </td><td>172</td><td> </td><td> </td><td> </td><td>(1,525</td><td>)</td><td> </td><td> </td><td>1,715</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Net loss available to common stockholders</td><td> </td><td> </td><td>$</td><td>(14,213</td><td>)</td><td> </td><td>$</td><td>(27,975</td><td>)</td><td> </td><td>$</td><td>(107,928</td><td>)</td><td> </td><td>$</td><td>(89,336</td><td>)</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Net loss per common share, basic and diluted</td><td> </td><td> </td><td>$</td><td>(0.23</td><td>)</td><td> </td><td>$</td><td>(38.63</td><td>)</td><td> </td><td>$</td><td>(4.66</td><td>)</td><td> </td><td>$</td><td>(143.47</td><td>)</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Weighted average common shares outstanding, basic and diluted</td><td> </td><td> </td><td> </td><td>62,122,283</td><td> </td><td> </td><td> </td><td>724,190</td><td> </td><td> </td><td> </td><td>23,136,172</td><td> </td><td> </td><td> </td><td>622,684</td><td> </td></tr><tr><td colspan=\"18\"> </td></tr></table> <table><tr><td colspan=\"6\"><strong>TONIX PHARMACEUTICALS HOLDING CORP.</strong><br/><strong>CONDENSED CONSOLIDATED BALANCE SHEETS</strong><br/><strong> (In Thousands)</strong><br/><strong>(Unaudited)</strong></td></tr><tr><td colspan=\"6\"> </td></tr><tr><td><strong> </strong></td><td colspan=\"2\"><strong>September 30, 2024</strong><strong><br/></strong></td><td> </td><td colspan=\"2\"><strong>December 31, 2023<sup><strong>1</strong></sup></strong><strong><br/></strong></td></tr><tr><td><strong>Assets</strong></td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Cash and cash equivalents</td><td>$   28,233</td><td> </td><td> </td><td>$   24,948</td><td> </td></tr><tr><td>Accounts Receivable, net</td><td>4,013</td><td> </td><td> </td><td>-</td><td> </td></tr><tr><td>Inventory</td><td>7,931</td><td> </td><td> </td><td>13,639</td><td> </td></tr><tr><td>Prepaid expenses and other</td><td>10,366</td><td> </td><td> </td><td>9,181</td><td> </td></tr><tr><td>Total current assets</td><td>50,543</td><td> </td><td> </td><td>47,768</td><td> </td></tr><tr><td>Other non-current assets</td><td>44,446</td><td> </td><td> </td><td>106,689</td><td> </td></tr><tr><td>Total assets</td><td>$   94,989</td><td> </td><td> </td><td>$   154,457</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><strong>Liabilities and stockholders' equity</strong></td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Total liabilities</td><td>$   20,778</td><td> </td><td> </td><td>$   48,932</td><td> </td></tr><tr><td>Stockholders' equity</td><td>74,211</td><td> </td><td> </td><td>105,525</td><td> </td></tr><tr><td>Total liabilities and stockholders' equity</td><td>$   94,989</td><td> </td><td> </td><td>$   154,457</td><td> </td></tr><tr><td colspan=\"6\"> </td></tr><tr><td colspan=\"6\"><sup>1</sup>The condensed consolidated balance sheet for the year ended December 31, 2023 has been derived from the audited financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.</td></tr><tr><td colspan=\"6\"> </td></tr></table> <p><strong>Investor Contact</strong></p> <p>Jessica Morris<br/>Tonix Pharmaceuticals<br/><u>investor.relations@tonixpharma.com</u> <br/>(862) 904-8182</p> <p>Peter Vozzo<br/>ICR Healthcare<br/><u>peter.vozzo@westwicke.com</u> <br/>(443) 213-0505</p> <p><strong>Media Contact</strong></p> <p>Ray Jordan<br/>Putnam Insights<br/>ray@putnaminsights.com<br/>(949) 245-5432</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MDk5YmE2ZGItNTRmMy00Y2JiLWExOTItNDIxODhkZjhjMjc4LTEwMjI2ODU=/tiny/Tonix-Pharmaceuticals-Holding-.png\"/></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4135":"资产管理与托管银行","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","BK4585":"ETF&股票定投概念","LU0210535034.USD":"摩根大通拉丁美洲基金","LU2346227817.USD":"BGF SUSTAINABLE GLOBAL INFRASTRUCTURE \"A2\" (USD) ACC","ASR":"墨西哥东南部机场","BK4174":"机场服务","CNS":"科恩-斯蒂尔斯金融","BK4583":"猴痘概念","BK4139":"生物科技","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4208":"复合型公用事业","BK4588":"碎股","FM":"iShares安硕MSCI前驱100 ETF","TNXP":"Tonix Pharmaceuticals Holding Co","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","ED":"爱迪生联合电气"},"source_url":"https://www.globenewswire.com/news-release/2024/12/16/2997705/28908/en/Tonix-Pharmaceuticals-Reports-Third-Quarter-2024-Financial-Results-and-Operational-Highlights.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2492611699","content_text":"Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studies Granted Fast Track Designation by FDA in July 2024 for TNX-102 SL, a centrally-acting, non-opioid analgesic; Fibromyalgia is a common chronic pain condition that affects mostly women Expect FDA decision in December 2024 on TNX-102 SL NDA acceptance for review and 2025 PDUFA date; If FDA-approved in 2025, TNX-102 SL would be the first new drug for fibromyalgia in more than 15 years Presented new data on potential mpox vaccine, TNX-801, in September and October 2024, demonstrating tolerability in immunocompromised animals; Previously reported studies showed a single-dose provided immune protection against a monkeypox challenge  Awarded U.S. Department of Defense (DoD) contract for up to $34 million over five years in July 2024 to develop a broad-spectrum antiviral drug; Received first payment from DTRA CHATHAM, N.J., Dec.  16, 2024  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced financial results for the third quarter ended September 30, 2024, and provided an overview of recent operational highlights. “With our recent NDA submission to the U.S. Food and Drug Administration (FDA), Tonix is excited about the potential of TNX-102 SL to become the first new drug treatment option in more than 15 years for the roughly 10 million adults in the U.S. suffering from fibromyalgia,” said Seth Lederman, M.D., Chief Executive Officer of Tonix. “FDA awarded TNX-102 SL Fast Track designation in the third quarter of 2024, which is intended to expedite FDA review of important new drugs to fill unmet needs for serious conditions. We look forward to next steps with FDA. If the NDA filing is accepted in December, we expect a decision on the marketing approval of TNX-102 SL for fibromyalgia in 2025.” Dr. Lederman continued, “As we continue to advance key pipeline products through a capital efficient strategy, we are excited to have announced collaborations with world-class institutions to advance the development of TNX-801, a potential mpox vaccine whose single-dose administration and other characteristics align closely with The World Health Organization’s preferred target product profile (TPP) criteria for mpox vaccines. The World Health Organization (WHO) previously announced the growing number of mpox cases constitutes a public health emergency of international concern (PHEIC), with clade 1b mpox strains now detected in 16 countries in Africa as well as in Sweden, Thailand, Singapore, India, England and Germany.” Key Product Candidates* -- Recent Highlights  Central Nervous System (CNS) Pipeline TNX-102 SL (cyclobenzaprine HCl sublingual tablets): 5.6 mg, once-daily at bedtime small molecule for the management of fibromyalgia (FM) – a centrally-acting, non-opioid analgesic. In October 2024, Tonix announced submission of the TNX-102 SL New Drug Application (NDA) for fibromyalgia to the FDA. The submission was based upon two Phase 3 studies of TNX-102 SL in fibromyalgia that showed statically significant reduction in the chronic, widespread pain associated with fibromyalgia. If approved by the FDA, TNX-102 SL would be the first member of a new class of analgesic drugs for fibromyalgia and the first new drug available for treating fibromyalgia in more than 15 years. Fibromyalgia affects more than 10 million adults in the U.S., most of whom are women.In September 2024, at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS 2024), the Company announced data highlighting the proprietary formulation technology and pharmacokinetic properties of TNX-102 SL, including composition and methods patents based on the proprietary eutectic1 formulation of TNX-102 SL that are expected to provide market exclusivity until at least 2034 in the U.S., EU, Japan, China and other jurisdictions. The eutectic protects cyclobenzaprine HCl from interacting with the basifying agent that is also part of the formulation and required for efficient transmucosal absorption. The formulation of TNX-102 SL was designed specifically for sublingual administration and transmucosal absorption for bedtime dosing to target disturbed sleep, improve pain and other fibromyalgia symptoms, while reducing the risk of daytime somnolence.In August 2024, at both the DoD’s 2024 Military Health System Research Symposium (MHSRS), and at the International Association for the Study of Pain’s (IASP’s) 2024 World Congress on Pain, Tonix announced additional data and analyses of TNX-102 SL for the management of fibromyalgia. TNX-102 SL had met the pre-specified primary endpoint in the Phase 3 RESILIENT study, significantly reducing daily pain compared to placebo (p-value=0.00005) in participants with fibromyalgia while demonstrating broad syndromal benefits with statistically significant improvement in all six pre-specified key secondary endpoints, including those related to improving sleep quality, reducing fatigue, and improving patient global ratings and overall fibromyalgia symptoms and function. TNX-102 SL was well tolerated with an adverse event profile comparable to prior studies and no new safety signals were observed.In July 2024, Tonix noted that, based on the new definition of Long COVID by the U.S. National Academies of Sciences, Engineering and Medicine (NASEM), fibromyalgia is a ‘diagnosable condition’ in people suffering from Long COVID. The Company believes that diagnosing fibromyalgia in Long COVID patients will increase the potential market for TNX-102 SL following approval as compared to market estimates from before the COVID-19 pandemic. TNX-102 SL for the treatment of acute stress reaction (ASR) and acute stress disorder (ASD), and prophylaxis against development of posttraumatic stress disorder (PTSD) In August 2024 at the DoD’s MHSRS conference, the Company presented clinical data and rationale supporting the potential for TNX-102 SL to be studied for the treatment of ASR and prevention of PTSD. Prior studies showed that treatment with TNX-102 SL showed effects on sleep and PTSD symptoms in PTSD patients at two and four weeks1. This supportive data on the effects of TNX-102 SL on reducing PTSD symptoms suggest early intervention immediately after trauma using TNX-102 SL has the potential to reduce ASR/ASD symptoms which are similar to those of PTSD2,3. Data from these trials support testing of TNX-102 SL within 24 hours of index trauma for effects on ASR symptoms and the subsequent incidence of PTSD.The DoD-funded Optimizing Acute Stress Reaction Interventions (OASIS) trial will be conducted by the University of North Carolina under an investigator-initiated investigational new drug (IND) application. The OASIS trial will examine the safety and efficacy of TNX-102 SL to reduce adverse posttraumatic neuropsychiatric sequelae among patients in the emergency department (ED) after a motor vehicle collision. Fourteen days of bedtime TNX-102 SL will be dosed and tested in the immediate aftermath of motor vehicle collision. The study will test the potential for TNX-102 SL to target trauma-related sleep disturbance and its ability to facilitate recovery from ASR and to prevent PTSD. The results may ultimately provide military personnel with a new treatment option that, when administered in the early aftermath of a traumatic event to individuals with ASR symptoms, improves warfighter function. TNX-1300 (recombinant double mutant cocaine esterase): biologic for life-threatening cocaine intoxication Tonix announced the first patient in the Phase 2 CATALYST study of TNX-1300 for the treatment of cocaine intoxication was enrolled in August 2024. CATALYST is a Phase 2 single-blind, placebo-controlled, proof-of-concept study in patients presenting to the emergency department. Topline results are expected in the first half of 2025.The National Institutes of Health (NIH)’s National Institute of Drug Abuse (NIDA) previously awarded Tonix a Cooperative Agreement grant for approximately $5 million from to support development of TNX-1300.TNX-1300 has been granted Breakthrough Therapy designation by the FDA. Infectious Disease Pipeline TNX-801 (recombinant horsepox virus, live vaccine): potential vaccine to protect against mpox disease and smallpox. In September 2024, at the DoD’s MHSRS conference and in October 2024 at the World Vaccine Congress in Barcelona, Spain, Tonix presented new data on potential mpox vaccine, TNX-801, demonstrating tolerability and no evidence of spreading to blood or tissues, even at high doses, in immunocompromised animals. TNX-801 is an attenuated live-virus vaccine based on synthesized horsepox that has been shown to provide single-dose immune protection against a monkeypox challenge. After a single-dose vaccination, TNX-801 prevented clinical disease and lesions, and also decreased shedding in the mouth and lungs of non-human primates after a lethal challenge with Clade Ia monkeypox. These findings are consistent with TNX-801 inducing mucosal immunity and suggest TNX-801 has the ability to block forward transmission.In August 2024, the WHO determined that the upsurge of mpox in a growing number of countries in Africa constitutes a public health emergency of international concern (PHEIC), the second such declaration in the past two years in response to transmission of the virus. Mpox cases of the new clade 1b mpox have since also been detected in Sweden, Thailand, Singapore, India, Germany and England.In September 2024, the Company announced that the WHO’s preferred TPP aligns with the characteristics of TNX-801. Key elements of the WHO draft TPP include single-dose, durable protection, administration without special equipment, and stability at ambient temperature. Other potential beneficial characteristics include the ability to limit forward transmission, use in case-contact vaccination strategies and suitability for use in immunocompromised individuals. Footnotes: The TNX-102 SL eutectic is a composition of matter based on co-penetration of cyclobenzaprine HCl and mannitol crystals and protected by 5 issued U.S patents: Nos. 9,636,408; 9,956,188; 10,117,936; 10,864,175; 11,839,594; 9,918,948; 11,826,321.Sullivan GM, et al. Randomized clinical trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related PTSD and the role of sleep quality in treatment response. Psychiatry Res. 2021 Jul;301:113974.Parmenter ME, et al. A phase 3, randomized, placebo-controlled, trial to evaluate the efficacy and safety of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related posttraumatic stress disorder. Psychiatry Res. 2024 (In Press). https://doi.org/10.1016/j.psychres.2024.115764 Corporate and Partnerships – Recent Highlights In November 2024, the Company announced that it has entered into a sponsored research agreement with the Kenya Medical Research Institute (KEMRI) to design, plan and seek regulatory approval for a Phase I clinical study in Kenya to test the safety, tolerability, and immunogenicity of TNX-801 (horsepox, live virus) as a vaccine to prevent mpox and smallpox. Tonix is expected be the sponsor and KEMRI is expected to lead the execution of the proposed clinical trial.In October 2024, the Company announced it entered into an artificial intelligence and machine learning drug discovery collaboration with X-Chem, Inc., a leader in small molecule drug discovery, to accelerate the development of small molecules as orally available host-targeted broad-spectrum medical countermeasures. Tonix’s TNX-4200 antiviral program focuses on the development of oral CD45 phosphatase inhibitors, with broad-spectrum activity against a range of viral families.In September 2024, Tonix announced the appointment of Thomas Englese as its new Executive Vice President, Commercial Operations. Mr. Englese brings significant leadership to Tonix across several functions, including commercial operations, sales and marketing, and launching and managing major brands through all stages of commercialization.   In August 2024, the Company announced a collaboration with Bilthoven Biologics (Bbio) to develop GMP manufacturing processes for TNX-801 as a potential mpox vaccine. Bbio is part of the world’s largest vaccine manufacturer, the Cyrus Poonawalla Group, which also includes the Serum Institute of India.   In July 2024, Tonix announced it had been awarded a DoD contract with a potential for up to $34 million over five years by DoD’s Defense Threat Reduction Agency (DTRA). The objective of the contract is to develop small molecule broad-spectrum antiviral agents for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix’s program will focus on optimization and development of its TNX-4200 program, to develop an orally available CD45 antagonist, with broad-spectrum efficacy against a range of viral families through preclinical evaluation. The program is expected to establish physicochemical properties, pharmacokinetics, and safety attributes to support an IIND submission and to fund a first-in-human Phase 1 clinical study. Marketed Products – Recent Highlights In September 2024, Tonix announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 12,097,183 to the Company, claiming use of a pre-filled autoinjector comprising a composition of Zembrace® SymTouch® for treating migraines via subcutaneous administration. This patent, excluding possible patent term extensions, is expected to fortify protection and market exclusivity into 2036.Tonix announced that the USPTO issued U.S. Patent No. 12,090,139 to the Company, claiming a pharmaceutical composition, a method of treating migraine via intranasal administration, and an intranasal delivery system for Tosymra®. This patent is expected to fortify protection and market exclusivity into 2030. Tonix Medicines launched a national educational campaign focusing on the link between migraine, gastroparesis, and the need for non-oral acute migraine therapies. Tonix Medicines is the only manufacturer with both a branded injectable and nasal spray indicated for the acute treatment of migraine with or without aura in adults. Financial - Recent Highlight As of September 30, 2024, Tonix had approximately $28.2 million of cash and cash equivalents, compared to approximately $24.9 million as of December 31, 2023. Additionally, Tonix had inventory totaling approximately $7.9 million as of September 30, 2024. Net cash used in operations was approximately $46.3 million for the nine months ended September 30, 2024, compared to approximately $79.7 million for the same period in 2023. Cash used in investing activities for the nine months ended September 30, 2024 was approximately $117,000 compared to $28.6 million for the same period in 2023. In July 2024, Tonix received net proceeds of approximately $3.5 million in a securities offering with certain institutional and retail investors. Additionally, during the three months ended September 30, 2024, Tonix sold approximately 134.5 million shares of common stock under the 2024 ATM Sales Agreement for net proceeds of approximately $41.8 million. Third Quarter 2024 Financial Results Net product revenue for the third quarter 2024 was approximately $2.8 million. Net product revenue consisted of combined net sales of Zembrace® SymTouch® and Tosymra®, which were acquired from Upsher-Smith Laboratories, LLC on June 30, 2023. Cost of sales for the third quarter 2024 was approximately $1.6 million. During the three months ended September 30, 2024, Tonix received its first payment from DTRA as part of its previously announced award from DTRA for up to $34 million over five years. Research and development expenses for the third quarter 2024 were approximately $9.1 million, compared to $21.0 million for the same period in 2023. This decrease is predominantly due to lower clinical, non-clinical and manufacturing expenses aligned with the Company’s capital efficient strategy. Selling, general and administrative expenses for the third quarter 2024 were approximately $7.7 million, compared to $8.7 million for the same period in 2023. The decrease was primarily due to lower employee-related expenses, transactional services and sales and marketing expenses partially offset by an increase in professional fees. Net loss available to common stockholders was approximately $14.2 million, or $0.23 per share, basic and diluted, for the third quarter 2024, compared to net loss available to common stockholders of $28.0 million, or $38.63 per share, basic and diluted, for the same period in 2023. The basic and diluted weighted average common shares outstanding for the third quarter 2024 was 62,122,283 compared to 724,190 shares for the same period in 2023. Tonix Pharmaceuticals Holding Corp.*Tonix is a fully-integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. We expect an FDA decision on the acceptance of the NDA for review and a PDUFA date in December and if accepted, a decision on NDA approval in 2025. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation and its development is supported by a grant from the U.S. National Institute of Drug Abuse and Addiction. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease, including TNX-2900 for Prader-Willi syndrome, and infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, MD. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults. * Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners. This press release and further information about Tonix can be found at www.tonixpharma.com. Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. TONIX PHARMACEUTICALS HOLDING CORP. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In Thousands, Except Share and Per Share Amounts)(unaudited)                     Three Months EndedSeptember 30,  Nine Months EndedSeptember 30,    2024  2023  2024  2023 REVENUE:                 Product revenue, net  $2,822  $3,989  $7,512  $3,989 COSTS AND EXPENSES:                 Cost of revenue   1,555   2,374   6,582   2,374 Research and development   9,114   21,050   31,675   69,535 Selling, general and administrative   7,707   8,712   24,519   23,131 Asset impairment charges   —   —   58,957   —     18,376   32,136   121,733   95,040                   Operating loss   (15,554)  (28,147)  (114,221)  (91,051)                  Grant income   1,668   —   1,668   — Gain on change in fair value of warrant liabilities   —   —   6,150   — Other (expense) income, net   (327)  172   (1,525)  1,715                   Net loss available to common stockholders  $(14,213) $(27,975) $(107,928) $(89,336)                  Net loss per common share, basic and diluted  $(0.23) $(38.63) $(4.66) $(143.47)                  Weighted average common shares outstanding, basic and diluted   62,122,283   724,190   23,136,172   622,684   TONIX PHARMACEUTICALS HOLDING CORP.CONDENSED CONSOLIDATED BALANCE SHEETS (In Thousands)(Unaudited)  September 30, 2024 December 31, 20231Assets     Cash and cash equivalents$   28,233  $   24,948 Accounts Receivable, net4,013  - Inventory7,931  13,639 Prepaid expenses and other10,366  9,181 Total current assets50,543  47,768 Other non-current assets44,446  106,689 Total assets$   94,989  $   154,457       Liabilities and stockholders' equity     Total liabilities$   20,778  $   48,932 Stockholders' equity74,211  105,525 Total liabilities and stockholders' equity$   94,989  $   154,457  1The condensed consolidated balance sheet for the year ended December 31, 2023 has been derived from the audited financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.  Investor Contact Jessica MorrisTonix Pharmaceuticalsinvestor.relations@tonixpharma.com (862) 904-8182 Peter VozzoICR Healthcarepeter.vozzo@westwicke.com (443) 213-0505 Media Contact Ray JordanPutnam Insightsray@putnaminsights.com(949) 245-5432","news_type":1},"isVote":1,"tweetType":1,"viewCount":613,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4141429963588842","authorId":"4141429963588842","name":"TigerGPT","avatar":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738","crmLevel":1,"crmLevelSwitch":0,"idStr":"4141429963588842","authorIdStr":"4141429963588842"},"content":"Based on the information available, it seems that there is no specific analysis or valuation data for Tonix Pharmaceuticals (TNXP) at the moment. However, there are some recent news articles related to the company: Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights: This article discusses Tonix Pharmaceuticals submitting a New Drug Application (NDA) to the FDA for TNX-102 SL for fibromyalgia. The company was also granted Fast Track Designation by the FDA for TNX-102 SL. NDA Filed for TNX-102 SL in Fibromyalgia: This article highlights the filing of the NDA for TNX-102 SL in fibromyalgia by Tonix Pharmaceuticals. Tonix Pharmaceuticals appoints Raudabaugh, Gould as VPs: Tonix Pharmaceuticals announced the expansion of its leadership team to support the launch of TNX-102 SL for the management of fibromyalgia. Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference: This article mentions Tonix Pharmaceuticals' participation in the NobleCon20 Investor Conference. Please note that the news articles provided are for informational purposes only and should not be considered as investment advice or a recommendation to hold Tonix Pharmaceuticals (TNXP) for the long term. Remember to conduct thorough research and analysis before making any investment decisions. If you require more up-to-date and comprehensive information, I recommend reviewing the stock quote page or consulting with a professional financial advisor.","text":"Based on the information available, it seems that there is no specific analysis or valuation data for Tonix Pharmaceuticals (TNXP) at the moment. However, there are some recent news articles related to the company: Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights: This article discusses Tonix Pharmaceuticals submitting a New Drug Application (NDA) to the FDA for TNX-102 SL for fibromyalgia. The company was also granted Fast Track Designation by the FDA for TNX-102 SL. NDA Filed for TNX-102 SL in Fibromyalgia: This article highlights the filing of the NDA for TNX-102 SL in fibromyalgia by Tonix Pharmaceuticals. Tonix Pharmaceuticals appoints Raudabaugh, Gould as VPs: Tonix Pharmaceuticals announced the expansion of its leadership team to support the launch of TNX-102 SL for the management of fibromyalgia. Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference: This article mentions Tonix Pharmaceuticals' participation in the NobleCon20 Investor Conference. Please note that the news articles provided are for informational purposes only and should not be considered as investment advice or a recommendation to hold Tonix Pharmaceuticals (TNXP) for the long term. Remember to conduct thorough research and analysis before making any investment decisions. If you require more up-to-date and comprehensive information, I recommend reviewing the stock quote page or consulting with a professional financial advisor.","html":"Based on the information available, it seems that there is no specific analysis or valuation data for Tonix Pharmaceuticals (TNXP) at the moment. However, there are some recent news articles related to the company: Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights: This article discusses Tonix Pharmaceuticals submitting a New Drug Application (NDA) to the FDA for TNX-102 SL for fibromyalgia. The company was also granted Fast Track Designation by the FDA for TNX-102 SL. NDA Filed for TNX-102 SL in Fibromyalgia: This article highlights the filing of the NDA for TNX-102 SL in fibromyalgia by Tonix Pharmaceuticals. Tonix Pharmaceuticals appoints Raudabaugh, Gould as VPs: Tonix Pharmaceuticals announced the expansion of its leadership team to support the launch of TNX-102 SL for the management of fibromyalgia. Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference: This article mentions Tonix Pharmaceuticals' participation in the NobleCon20 Investor Conference. Please note that the news articles provided are for informational purposes only and should not be considered as investment advice or a recommendation to hold Tonix Pharmaceuticals (TNXP) for the long term. Remember to conduct thorough research and analysis before making any investment decisions. If you require more up-to-date and comprehensive information, I recommend reviewing the stock quote page or consulting with a professional financial advisor."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":382168804778120,"gmtCreate":1734334342051,"gmtModify":1734334345487,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/382168804778120","repostId":"382184588726600","repostType":1,"repost":{"id":382184588726600,"gmtCreate":1734282328563,"gmtModify":1734328202421,"author":{"id":"4171900329979952","authorId":"4171900329979952","name":"Barcode","avatar":"https://community-static.tradeup.com/news/6688d8fb4c2a255e3b901e79755e56df","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4171900329979952","authorIdStr":"4171900329979952"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/MARA\">$MARA Holdings(MARA)$</a> <a href=\"https://ttm.financial/S/RIOT\">$Riot Platforms(RIOT)$</a> <a href=\"https://ttm.financial/S/WULF\">$TeraWulf Inc.(WULF)$</a> <a href=\"https://ttm.financial/S/CLSK\">$CleanSpark, Inc.(CLSK)$</a> <a href=\"https://ttm.financial/S/HUT\">$Hut 8 Mining Corp(HUT)$</a> $IREN 🔺📈 🅱️ U Ł Ł ł $ Ҥ 🔺 🧭🗺️🎯⛏️ Miner Fib Levels Mapped: Follow the BC BTC Miner Map Cycle to Peak Profits! 🚀💰🧭🗺️ 🔥 $MARA:&nbsp; 🔑 Key levels: $22.10, $23.18, $24.57 ~ 🥊🤜&nbsp;knock out that $24.57 level and we move again 🔺📈. Handle forming on the 4hr chart. ⚡ $RIOT:&nbsp; 🔑 Key levels: $13.15, $13.94, $14.29-$14.54.&nbsp; Inverse Head &amp; Shoulders (IHS) set up. 💎 $WULF:&nbsp; I love this set-up! Harmonic potential on a C-to-D leg. 🔑 Key levels: $8.90 then $10,","listText":"<a href=\"https://ttm.financial/S/MARA\">$MARA Holdings(MARA)$</a> <a href=\"https://ttm.financial/S/RIOT\">$Riot Platforms(RIOT)$</a> <a href=\"https://ttm.financial/S/WULF\">$TeraWulf Inc.(WULF)$</a> <a href=\"https://ttm.financial/S/CLSK\">$CleanSpark, Inc.(CLSK)$</a> <a href=\"https://ttm.financial/S/HUT\">$Hut 8 Mining Corp(HUT)$</a> $IREN 🔺📈 🅱️ U Ł Ł ł $ Ҥ 🔺 🧭🗺️🎯⛏️ Miner Fib Levels Mapped: Follow the BC BTC Miner Map Cycle to Peak Profits! 🚀💰🧭🗺️ 🔥 $MARA:&nbsp; 🔑 Key levels: $22.10, $23.18, $24.57 ~ 🥊🤜&nbsp;knock out that $24.57 level and we move again 🔺📈. Handle forming on the 4hr chart. ⚡ $RIOT:&nbsp; 🔑 Key levels: $13.15, $13.94, $14.29-$14.54.&nbsp; Inverse Head &amp; Shoulders (IHS) set up. 💎 $WULF:&nbsp; I love this set-up! Harmonic potential on a C-to-D leg. 🔑 Key levels: $8.90 then $10,","text":"$MARA Holdings(MARA)$ $Riot Platforms(RIOT)$ $TeraWulf Inc.(WULF)$ $CleanSpark, Inc.(CLSK)$ $Hut 8 Mining Corp(HUT)$ $IREN 🔺📈 🅱️ U Ł Ł ł $ Ҥ 🔺 🧭🗺️🎯⛏️ Miner Fib Levels Mapped: Follow the BC BTC Miner Map Cycle to Peak Profits! 🚀💰🧭🗺️ 🔥 $MARA: 🔑 Key levels: $22.10, $23.18, $24.57 ~ 🥊🤜 knock out that $24.57 level and we move again 🔺📈. Handle forming on the 4hr chart. ⚡ $RIOT: 🔑 Key levels: $13.15, $13.94, $14.29-$14.54. Inverse Head & Shoulders (IHS) set up. 💎 $WULF: I love this set-up! Harmonic potential on a C-to-D leg. 🔑 Key levels: $8.90 then $10,","images":[{"img":"https://community-static.tradeup.com/news/fc3b1d882744e5b5aa4e5cfb695d8b1e","width":"1269","height":"938"},{"img":"https://community-static.tradeup.com/news/37b632f4937a284d8adc93f2a664b16b","width":"893","height":"796"},{"img":"https://community-static.tradeup.com/news/750d19511e5fb0569fe41a136dea5068","width":"1263","height":"931"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/382184588726600","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":235,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":382149899346088,"gmtCreate":1734329728350,"gmtModify":1734329732930,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"Replying to <a href=\"https://ttm.financial/U/4178332581629092\">@Boybabyrage</a>:Yes bro we have made strong decisions. Cheers bro.. Wish you wealthy trading//<a href=\"https://ttm.financial/U/4178332581629092\">@Boybabyrage</a>:hahaha good that we hold back then , cheers bro","listText":"Replying to <a href=\"https://ttm.financial/U/4178332581629092\">@Boybabyrage</a>:Yes bro we have made strong decisions. Cheers bro.. Wish you wealthy trading//<a href=\"https://ttm.financial/U/4178332581629092\">@Boybabyrage</a>:hahaha good that we hold back then , cheers bro","text":"Replying to @Boybabyrage:Yes bro we have made strong decisions. Cheers bro.. Wish you wealthy trading//@Boybabyrage:hahaha good that we hold back then , cheers bro","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/382149899346088","repostId":"382306116657496","repostType":1,"repost":{"id":382306116657496,"gmtCreate":1734313280872,"gmtModify":1734314437962,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v> go go&nbsp;<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a>&nbsp;<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v> go go&nbsp;<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a>&nbsp;<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$Tonix Pharmaceuticals(TNXP)$ go go @TigerGPT $Tonix Pharmaceuticals(TNXP)$","images":[{"img":"https://community-static.tradeup.com/news/55dff79059585e883aa3822ef60623d7","width":"1068","height":"1112"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/382306116657496","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":348,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":382306116657496,"gmtCreate":1734313280872,"gmtModify":1734314437962,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v> go go&nbsp;<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a>&nbsp;<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v> go go&nbsp;<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a>&nbsp;<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$Tonix Pharmaceuticals(TNXP)$ go go @TigerGPT $Tonix Pharmaceuticals(TNXP)$","images":[{"img":"https://community-static.tradeup.com/news/55dff79059585e883aa3822ef60623d7","width":"1068","height":"1112"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":76,"commentSize":5,"repostSize":190,"link":"https://ttm.financial/post/382306116657496","isVote":1,"tweetType":1,"viewCount":4329,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"content":"hahaha good that we hold back then , cheers bro","text":"hahaha good that we hold back then , cheers bro","html":"hahaha good that we hold back then , cheers bro"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":380534752395336,"gmtCreate":1733955039574,"gmtModify":1733974294402,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TBLA\">$Taboola Com Ltd(TBLA)$</a> <a href=\"https://ttm.financial/S/TBLA\">$Taboola Com Ltd(TBLA)$</a> still not selling <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/TBLA\">$Taboola Com Ltd(TBLA)$</a> <a href=\"https://ttm.financial/S/TBLA\">$Taboola Com Ltd(TBLA)$</a> still not selling <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a>&nbsp;","text":"$Taboola Com Ltd(TBLA)$ $Taboola Com Ltd(TBLA)$ still not selling @Barcode @TigerGPT","images":[{"img":"https://community-static.tradeup.com/news/2ee79339e0fd3e4e5690e804a861d5f0","width":"327","height":"545"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":14,"commentSize":1,"repostSize":1,"link":"https://ttm.financial/post/380534752395336","isVote":1,"tweetType":1,"viewCount":464,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4141429963588842","authorId":"4141429963588842","name":"TigerGPT","avatar":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738","crmLevel":1,"crmLevelSwitch":0,"idStr":"4141429963588842","authorIdStr":"4141429963588842"},"content":"Based on the latest information available for Taboola Com Ltd (TBLA): Stock Name: Taboola Com Ltd Stock Code: TBLA Stock Price: $4.26 (USD) Yesterday's Closing Price: $4.08 (USD) 52-Week High: $5.00 (USD) 52-Week Low: $2.87 (USD) Market Capitalization: $1.43 billion (USD) Circulating Market Cap: $769.68 million (USD) Total Share Capital: 336.21 million Float Share Capital: 180.68 million Price-to-Earnings Ratio (TTM): -44.277 Price-to-Sales Ratio (TTM): 0.85 Price-to-Book Ratio: 1.42 Earnings per Share (LYR): -$0.24 Earnings per Share (TTM): -$0.10 Return on Assets (ROA): -0.46% Return on Equity (ROE): -3.19% Trading Volume: 2.43 million shares Trading Value: $10.29 million (USD) Volume Ratio: 1.39 Analyst Recommendations: 1 recommend 5 buy 1 hold Analyst Target Price: Mean: $5.33 (USD) Low: $5.00 (USD) High: $6.00 (USD) Recent News: Taboola Signs New Content Recommendations Deal With Future, Extending Partnership Into 12th Year Read more Taboola.com Signs New 3-Year Deal With WeatherBug Read more Taboola and WeatherBug Announce New, Exclusive Multi-Year Deal Read more Please note that the stock information provided is for reference purposes only and does not constitute investment advice. It is recommended to conduct thorough research and analysis before making any investment decisions.","text":"Based on the latest information available for Taboola Com Ltd (TBLA): Stock Name: Taboola Com Ltd Stock Code: TBLA Stock Price: $4.26 (USD) Yesterday's Closing Price: $4.08 (USD) 52-Week High: $5.00 (USD) 52-Week Low: $2.87 (USD) Market Capitalization: $1.43 billion (USD) Circulating Market Cap: $769.68 million (USD) Total Share Capital: 336.21 million Float Share Capital: 180.68 million Price-to-Earnings Ratio (TTM): -44.277 Price-to-Sales Ratio (TTM): 0.85 Price-to-Book Ratio: 1.42 Earnings per Share (LYR): -$0.24 Earnings per Share (TTM): -$0.10 Return on Assets (ROA): -0.46% Return on Equity (ROE): -3.19% Trading Volume: 2.43 million shares Trading Value: $10.29 million (USD) Volume Ratio: 1.39 Analyst Recommendations: 1 recommend 5 buy 1 hold Analyst Target Price: Mean: $5.33 (USD) Low: $5.00 (USD) High: $6.00 (USD) Recent News: Taboola Signs New Content Recommendations Deal With Future, Extending Partnership Into 12th Year Read more Taboola.com Signs New 3-Year Deal With WeatherBug Read more Taboola and WeatherBug Announce New, Exclusive Multi-Year Deal Read more Please note that the stock information provided is for reference purposes only and does not constitute investment advice. It is recommended to conduct thorough research and analysis before making any investment decisions.","html":"Based on the latest information available for Taboola Com Ltd (TBLA): Stock Name: Taboola Com Ltd Stock Code: TBLA Stock Price: $4.26 (USD) Yesterday's Closing Price: $4.08 (USD) 52-Week High: $5.00 (USD) 52-Week Low: $2.87 (USD) Market Capitalization: $1.43 billion (USD) Circulating Market Cap: $769.68 million (USD) Total Share Capital: 336.21 million Float Share Capital: 180.68 million Price-to-Earnings Ratio (TTM): -44.277 Price-to-Sales Ratio (TTM): 0.85 Price-to-Book Ratio: 1.42 Earnings per Share (LYR): -$0.24 Earnings per Share (TTM): -$0.10 Return on Assets (ROA): -0.46% Return on Equity (ROE): -3.19% Trading Volume: 2.43 million shares Trading Value: $10.29 million (USD) Volume Ratio: 1.39 Analyst Recommendations: 1 recommend 5 buy 1 hold Analyst Target Price: Mean: $5.33 (USD) Low: $5.00 (USD) High: $6.00 (USD) Recent News: Taboola Signs New Content Recommendations Deal With Future, Extending Partnership Into 12th Year Read more Taboola.com Signs New 3-Year Deal With WeatherBug Read more Taboola and WeatherBug Announce New, Exclusive Multi-Year Deal Read more Please note that the stock information provided is for reference purposes only and does not constitute investment advice. It is recommended to conduct thorough research and analysis before making any investment decisions."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":380481956446488,"gmtCreate":1733927670736,"gmtModify":1733927862552,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/GOEV\">$Canoo Inc.(GOEV)$&nbsp;</a><v-v data-views=\"0\"></v-v> Shit big shit<a href=\"https://ttm.financial/S/GOEV\">$Canoo Inc.(GOEV)$&nbsp;</a>&nbsp; <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> boss any luck here <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/GOEV\">$Canoo Inc.(GOEV)$&nbsp;</a><v-v data-views=\"0\"></v-v> Shit big shit<a href=\"https://ttm.financial/S/GOEV\">$Canoo Inc.(GOEV)$&nbsp;</a>&nbsp; <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> boss any luck here <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a>&nbsp;","text":"$Canoo Inc.(GOEV)$ Shit big shit$Canoo Inc.(GOEV)$ @Barcode boss any luck here @TigerGPT","images":[{"img":"https://community-static.tradeup.com/news/f36fb756dd117ca9933ef74fa066a6eb","width":"327","height":"545"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/380481956446488","isVote":1,"tweetType":1,"viewCount":515,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4141429963588842","authorId":"4141429963588842","name":"TigerGPT","avatar":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738","crmLevel":1,"crmLevelSwitch":0,"idStr":"4141429963588842","authorIdStr":"4141429963588842"},"content":"Canoo Inc. (GOEV) has experienced a recent movement in its stock price. After analyzing the available news, we found an article discussing the Wall Street analysts' views on investing in Canoo. The article indicates that Canoo currently has an average brokerage recommendation (ABR) of 1.57, which falls between Strong Buy and Buy. Out of the seven recommendations that make up the ABR, five are Strong Buy, representing 71.4% of all recommendations. It's worth noting that brokerage firms may have a vested interest in the stocks they cover, which can result in a positive bias in their analysts' ratings. You can read the full article here. Please keep in mind that the movement in Canoo's stock price may also be influenced by factors such as stock capital flow. If there are no significant news articles available or the news articles do not directly explain the stock movement, stock capital flow could be a potential reason. Remember that stock movements can be affected by various factors and can change rapidly. It is important to conduct thorough research and analysis before making any investment decisions. Note: The information provided is for reference purposes only and does not constitute investment advice.","text":"Canoo Inc. (GOEV) has experienced a recent movement in its stock price. After analyzing the available news, we found an article discussing the Wall Street analysts' views on investing in Canoo. The article indicates that Canoo currently has an average brokerage recommendation (ABR) of 1.57, which falls between Strong Buy and Buy. Out of the seven recommendations that make up the ABR, five are Strong Buy, representing 71.4% of all recommendations. It's worth noting that brokerage firms may have a vested interest in the stocks they cover, which can result in a positive bias in their analysts' ratings. You can read the full article here. Please keep in mind that the movement in Canoo's stock price may also be influenced by factors such as stock capital flow. If there are no significant news articles available or the news articles do not directly explain the stock movement, stock capital flow could be a potential reason. Remember that stock movements can be affected by various factors and can change rapidly. It is important to conduct thorough research and analysis before making any investment decisions. Note: The information provided is for reference purposes only and does not constitute investment advice.","html":"Canoo Inc. (GOEV) has experienced a recent movement in its stock price. After analyzing the available news, we found an article discussing the Wall Street analysts' views on investing in Canoo. The article indicates that Canoo currently has an average brokerage recommendation (ABR) of 1.57, which falls between Strong Buy and Buy. Out of the seven recommendations that make up the ABR, five are Strong Buy, representing 71.4% of all recommendations. It's worth noting that brokerage firms may have a vested interest in the stocks they cover, which can result in a positive bias in their analysts' ratings. You can read the full article here. Please keep in mind that the movement in Canoo's stock price may also be influenced by factors such as stock capital flow. If there are no significant news articles available or the news articles do not directly explain the stock movement, stock capital flow could be a potential reason. Remember that stock movements can be affected by various factors and can change rapidly. It is important to conduct thorough research and analysis before making any investment decisions. Note: The information provided is for reference purposes only and does not constitute investment advice."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":379716235325704,"gmtCreate":1733730883980,"gmtModify":1733730887359,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$ </a> early Christmas&nbsp;","listText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$ </a> early Christmas&nbsp;","text":"$Tiger Brokers(TIGR)$ early Christmas","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379716235325704","isVote":1,"tweetType":1,"viewCount":223,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":382603205132640,"gmtCreate":1734443997221,"gmtModify":1734492329425,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a> 5$ soon&nbsp;<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a>&nbsp;<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a>&nbsp;<a href=\"https://ttm.financial/U/4106547232749330\">@Tiger_SG </a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a> 5$ soon&nbsp;<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a>&nbsp;<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a>&nbsp;<a href=\"https://ttm.financial/U/4106547232749330\">@Tiger_SG </a>&nbsp;","text":"$Tonix Pharmaceuticals(TNXP)$ 5$ soon @Barcode @TigerGPT @Tiger_SG","images":[{"img":"https://community-static.tradeup.com/news/80fb0a6db8ee66d377f8a3a2a33ea29e","width":"1068","height":"1112"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":104,"commentSize":17,"repostSize":723,"link":"https://ttm.financial/post/382603205132640","isVote":1,"tweetType":1,"viewCount":14499,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3561775119462661","authorId":"3561775119462661","name":"700k","avatar":"https://community-static.tradeup.com/news/c822cf27b8c85ca6e6d8dd110dc73ab1","crmLevel":3,"crmLevelSwitch":1,"idStr":"3561775119462661","authorIdStr":"3561775119462661"},"content":"hope you have sold it when it reach above $1. I believe retail trader and investors sold their share after it spike","text":"hope you have sold it when it reach above $1. I believe retail trader and investors sold their share after it spike","html":"hope you have sold it when it reach above $1. I believe retail trader and investors sold their share after it spike"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":382306116657496,"gmtCreate":1734313280872,"gmtModify":1734314437962,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v> go go&nbsp;<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a>&nbsp;<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v> go go&nbsp;<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a>&nbsp;<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$Tonix Pharmaceuticals(TNXP)$ go go @TigerGPT $Tonix Pharmaceuticals(TNXP)$","images":[{"img":"https://community-static.tradeup.com/news/55dff79059585e883aa3822ef60623d7","width":"1068","height":"1112"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":76,"commentSize":5,"repostSize":190,"link":"https://ttm.financial/post/382306116657496","isVote":1,"tweetType":1,"viewCount":4329,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"content":"hahaha good that we hold back then , cheers bro","text":"hahaha good that we hold back then , cheers bro","html":"hahaha good that we hold back then , cheers bro"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":365761250451480,"gmtCreate":1730297749639,"gmtModify":1730297754803,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/DJT\">$Trump Media &amp; Technology(DJT)$&nbsp;</a><v-v data-views=\"1\"></v-v> it's glitch.. 60$ is loading.. @<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a> you're strong analysis required here to save me 😭😭😭<a href=\"https://ttm.financial/S/DJT\">$Trump Media &amp; Technology(DJT)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/DJT\">$Trump Media &amp; Technology(DJT)$&nbsp;</a><v-v data-views=\"1\"></v-v> it's glitch.. 60$ is loading.. @<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a> you're strong analysis required here to save me 😭😭😭<a href=\"https://ttm.financial/S/DJT\">$Trump Media &amp; Technology(DJT)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$Trump Media & Technology(DJT)$ it's glitch.. 60$ is loading.. @@Barcode you're strong analysis required here to save me 😭😭😭$Trump Media & Technology(DJT)$","images":[{"img":"https://community-static.tradeup.com/news/8304d61ca4c1f496dff7959b8d678db8","width":"1068","height":"1112"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":30,"commentSize":2,"repostSize":46,"link":"https://ttm.financial/post/365761250451480","isVote":1,"tweetType":1,"viewCount":1384,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4171900329979952","authorId":"4171900329979952","name":"Barcode","avatar":"https://community-static.tradeup.com/news/6688d8fb4c2a255e3b901e79755e56df","crmLevel":1,"crmLevelSwitch":0,"idStr":"4171900329979952","authorIdStr":"4171900329979952"},"content":"Hey Kallu, I haven’t been in DJT for a while. Too risky now after it reached over my target 🎯. Stay safe. Cheers, BC","text":"Hey Kallu, I haven’t been in DJT for a while. Too risky now after it reached over my target 🎯. Stay safe. Cheers, BC","html":"Hey Kallu, I haven’t been in DJT for a while. Too risky now after it reached over my target 🎯. Stay safe. Cheers, BC"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":360392226762880,"gmtCreate":1729005597010,"gmtModify":1729090802934,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"\"Enjoying the bloodbath today, and it will continue until the end of the week. Prepared for everything.\"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$&nbsp;</a><a href=\"https://ttm.financial/S/ASPN\">$Aspen Aerogels(ASPN)$</a> <a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a><a href=\"https://ttm.financial/S/NDX\">$NASDAQ 100(NDX)$&nbsp;</a>&nbsp;<a href=\"https://ttm.financial/S/.SPX\">$.SPX(.SPX)$&nbsp;</a>&nbsp; <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> Why!!!&nbsp;","listText":"\"Enjoying the bloodbath today, and it will continue until the end of the week. Prepared for everything.\"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$&nbsp;</a><a href=\"https://ttm.financial/S/ASPN\">$Aspen Aerogels(ASPN)$</a> <a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a><a href=\"https://ttm.financial/S/NDX\">$NASDAQ 100(NDX)$&nbsp;</a>&nbsp;<a href=\"https://ttm.financial/S/.SPX\">$.SPX(.SPX)$&nbsp;</a>&nbsp; <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> Why!!!&nbsp;","text":"\"Enjoying the bloodbath today, and it will continue until the end of the week. Prepared for everything.\"$NVIDIA Corp(NVDA)$ $Aspen Aerogels(ASPN)$ $Tiger Brokers(TIGR)$$NASDAQ 100(NDX)$ $.SPX(.SPX)$ @Barcode @TigerGPT Why!!!","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":16,"commentSize":10,"repostSize":40,"link":"https://ttm.financial/post/360392226762880","isVote":1,"tweetType":1,"viewCount":2574,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4171900329979952","authorId":"4171900329979952","name":"Barcode","avatar":"https://community-static.tradeup.com/news/6688d8fb4c2a255e3b901e79755e56df","crmLevel":1,"crmLevelSwitch":0,"idStr":"4171900329979952","authorIdStr":"4171900329979952"},"content":"I said the dip was coming in October around this period and what a gift to catch more NVDA shares on the dip. October is notorious since 2009 for weakness. Technically still is Seasonal weakness even though the market has been strong. We've had a huge run up and a drop was on the cards. Buy the dip!","text":"I said the dip was coming in October around this period and what a gift to catch more NVDA shares on the dip. October is notorious since 2009 for weakness. Technically still is Seasonal weakness even though the market has been strong. We've had a huge run up and a drop was on the cards. Buy the dip!","html":"I said the dip was coming in October around this period and what a gift to catch more NVDA shares on the dip. October is notorious since 2009 for weakness. Technically still is Seasonal weakness even though the market has been strong. We've had a huge run up and a drop was on the cards. Buy the dip!"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":373078257447032,"gmtCreate":1732093999131,"gmtModify":1732094757800,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a>&nbsp;<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a>&nbsp;<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a>&nbsp;<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a>&nbsp;<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a>&nbsp;","text":"$Tonix Pharmaceuticals(TNXP)$ $Tonix Pharmaceuticals(TNXP)$ @Barcode @TigerGPT $Tonix Pharmaceuticals(TNXP)$","images":[{"img":"https://community-static.tradeup.com/news/22666e4b24ab40af2202a7bc068e0ea3","width":"1068","height":"1112"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":4,"repostSize":1,"link":"https://ttm.financial/post/373078257447032","isVote":1,"tweetType":1,"viewCount":623,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4141429963588842","authorId":"4141429963588842","name":"TigerGPT","avatar":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738","crmLevel":1,"crmLevelSwitch":0,"idStr":"4141429963588842","authorIdStr":"4141429963588842"},"content":"Tonix Pharmaceuticals (TNXP) Overview Tonix Pharmaceuticals Holding Corp (TNXP) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to address challenging healthcare needs. They have a pipeline of development candidates targeting various central nervous system (CNS) and immunological conditions. Recent News and Events Here are some of the recent news and events related to Tonix Pharmaceuticals: Winter 2024 Investor Summit Presentation: Tonix Pharmaceuticals announced that Jessica Morris, the Chief Operating Officer, will be presenting at the Winter 2024 Investor Summit Virtual on November 21, 2024. This event provides an opportunity for the company to share updates and insights with investors. Link to Article ACR Convergence 2024 Annual Meeting: Tonix Pharmaceuticals presented data and analyses of TNX-102 SL effects in a poster presentation at the ACR Convergence 2024 Annual Meeting, held from November 14-19, 2024. This meeting brings together experts in rheumatology research to discuss the latest advancements in the field. Link to Article Third Quarter 2024 Earnings: Eton Pharmaceuticals (NASDAQ: ETON), a different company, reported its third-quarter 2024 earnings results. Please note that this information is unrelated to Tonix Pharmaceuticals. Link to Article Tonix Pharmaceuticals Q3 2024 Earnings: Tonix Pharmaceuticals reported quarterly losses of $(0.23) per share, beating the analyst consensus estimate of $(2.93) by 92.15 percent. The company reported quarterly sales of $2.80 million, slightly missing the estimate of $3.08 million. Link to Article BIO-Europe® 2024 Presentation: Tonix Pharmaceuticals announced that it would be presenting at BIO-Europe® 2024. This conference offers a platform for biotech and pharmaceutical companies to discuss partnership opportunities and advancements in the industry. Link to Article Conclusion Tonix Pharmaceuticals has been active in participating in investor conferences, presenting data, and releasing earnings results. While it's essential to consider the recent news and events, it's also vital to conduct thorough research, evaluate the company's financial health, and assess the potential risks before making any investment decisions. Risk Disclaimer: The information provided above is for reference purposes only and does not constitute investment advice. It is crucial to conduct your own research and consult with a qualified financial advisor before making any investment decisions.","text":"Tonix Pharmaceuticals (TNXP) Overview Tonix Pharmaceuticals Holding Corp (TNXP) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to address challenging healthcare needs. They have a pipeline of development candidates targeting various central nervous system (CNS) and immunological conditions. Recent News and Events Here are some of the recent news and events related to Tonix Pharmaceuticals: Winter 2024 Investor Summit Presentation: Tonix Pharmaceuticals announced that Jessica Morris, the Chief Operating Officer, will be presenting at the Winter 2024 Investor Summit Virtual on November 21, 2024. This event provides an opportunity for the company to share updates and insights with investors. Link to Article ACR Convergence 2024 Annual Meeting: Tonix Pharmaceuticals presented data and analyses of TNX-102 SL effects in a poster presentation at the ACR Convergence 2024 Annual Meeting, held from November 14-19, 2024. This meeting brings together experts in rheumatology research to discuss the latest advancements in the field. Link to Article Third Quarter 2024 Earnings: Eton Pharmaceuticals (NASDAQ: ETON), a different company, reported its third-quarter 2024 earnings results. Please note that this information is unrelated to Tonix Pharmaceuticals. Link to Article Tonix Pharmaceuticals Q3 2024 Earnings: Tonix Pharmaceuticals reported quarterly losses of $(0.23) per share, beating the analyst consensus estimate of $(2.93) by 92.15 percent. The company reported quarterly sales of $2.80 million, slightly missing the estimate of $3.08 million. Link to Article BIO-Europe® 2024 Presentation: Tonix Pharmaceuticals announced that it would be presenting at BIO-Europe® 2024. This conference offers a platform for biotech and pharmaceutical companies to discuss partnership opportunities and advancements in the industry. Link to Article Conclusion Tonix Pharmaceuticals has been active in participating in investor conferences, presenting data, and releasing earnings results. While it's essential to consider the recent news and events, it's also vital to conduct thorough research, evaluate the company's financial health, and assess the potential risks before making any investment decisions. Risk Disclaimer: The information provided above is for reference purposes only and does not constitute investment advice. It is crucial to conduct your own research and consult with a qualified financial advisor before making any investment decisions.","html":"Tonix Pharmaceuticals (TNXP) Overview Tonix Pharmaceuticals Holding Corp (TNXP) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to address challenging healthcare needs. They have a pipeline of development candidates targeting various central nervous system (CNS) and immunological conditions. Recent News and Events Here are some of the recent news and events related to Tonix Pharmaceuticals: Winter 2024 Investor Summit Presentation: Tonix Pharmaceuticals announced that Jessica Morris, the Chief Operating Officer, will be presenting at the Winter 2024 Investor Summit Virtual on November 21, 2024. This event provides an opportunity for the company to share updates and insights with investors. Link to Article ACR Convergence 2024 Annual Meeting: Tonix Pharmaceuticals presented data and analyses of TNX-102 SL effects in a poster presentation at the ACR Convergence 2024 Annual Meeting, held from November 14-19, 2024. This meeting brings together experts in rheumatology research to discuss the latest advancements in the field. Link to Article Third Quarter 2024 Earnings: Eton Pharmaceuticals (NASDAQ: ETON), a different company, reported its third-quarter 2024 earnings results. Please note that this information is unrelated to Tonix Pharmaceuticals. Link to Article Tonix Pharmaceuticals Q3 2024 Earnings: Tonix Pharmaceuticals reported quarterly losses of $(0.23) per share, beating the analyst consensus estimate of $(2.93) by 92.15 percent. The company reported quarterly sales of $2.80 million, slightly missing the estimate of $3.08 million. Link to Article BIO-Europe® 2024 Presentation: Tonix Pharmaceuticals announced that it would be presenting at BIO-Europe® 2024. This conference offers a platform for biotech and pharmaceutical companies to discuss partnership opportunities and advancements in the industry. Link to Article Conclusion Tonix Pharmaceuticals has been active in participating in investor conferences, presenting data, and releasing earnings results. While it's essential to consider the recent news and events, it's also vital to conduct thorough research, evaluate the company's financial health, and assess the potential risks before making any investment decisions. Risk Disclaimer: The information provided above is for reference purposes only and does not constitute investment advice. It is crucial to conduct your own research and consult with a qualified financial advisor before making any investment decisions."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":357784684560448,"gmtCreate":1728359249847,"gmtModify":1728359254332,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/VINC\">$Vincera Pharma, Inc.(VINC)$</a> buy soon before the blast&nbsp;","listText":"<a href=\"https://ttm.financial/S/VINC\">$Vincera Pharma, Inc.(VINC)$</a> buy soon before the blast&nbsp;","text":"$Vincera Pharma, Inc.(VINC)$ buy soon before the blast","images":[{"img":"https://community-static.tradeup.com/news/2cc8c7a2c9b9764c2e5e8ce88f4561a9"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/357784684560448","repostId":"2473439200","repostType":2,"repost":{"id":"2473439200","kind":"highlight","weMediaInfo":{"introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"media_name":"MT Newswires Live","id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"pubTimestamp":1728335132,"share":"https://ttm.financial/m/news/2473439200?lang=&edition=fundamental","pubTime":"2024-10-08 05:05","market":"fut","language":"en","title":"Vincerx Pharma Reports 'Positive' Initial Clinical Data on Leukemia Drug; Shares Jump After Hours","url":"https://stock-news.laohu8.com/highlight/detail?id=2473439200","media":"MT Newswires Live","summary":"Vincerx Pharma (VINC) said its VIP943 leukemia drug showed \"promising safety and tolerability,\" achieving two complete responses to date in a phase 1 dose-escalation studyThe VIP943 antibody-drug conj","content":"<html><body><p> Vincerx Pharma (VINC) said its VIP943 leukemia drug showed \"promising safety and tolerability,\" achieving two complete responses to date in a phase 1 dose-escalation study</p><p>The VIP943 antibody-drug conjugate is being evaluated in relapsed/refractory acute myeloid leukemia, higher-risk myelodysplastic syndrome and B-cell acute lymphoblastic leukemia, the company said Monday in a statement.</p><p>Another data update is expected by the end of the year, the company said.</p><p>In an update on VIP236 being evaluated in a first-in-human, phase 1 dose-escalation study as a monotherapy in patients with advanced solid tumors, the company said it intends to pursue a strategic partner to \"champion its future development\" in order to focus on VIP943.</p><p>Vincerx expects a cash runway into early 2025.</p><p>Shares of the company jumped 15% in after-hours activity.</p><p>Price: 0.8000, Change: +0.10, Percent Change: +14.61</p></body></html>","source":"mtnewswires_news","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vincerx Pharma Reports 'Positive' Initial Clinical Data on Leukemia Drug; Shares Jump After Hours</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVincerx Pharma Reports 'Positive' Initial Clinical Data on Leukemia Drug; Shares Jump After Hours\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-10-08 05:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Vincerx Pharma (VINC) said its VIP943 leukemia drug showed \"promising safety and tolerability,\" achieving two complete responses to date in a phase 1 dose-escalation study</p><p>The VIP943 antibody-drug conjugate is being evaluated in relapsed/refractory acute myeloid leukemia, higher-risk myelodysplastic syndrome and B-cell acute lymphoblastic leukemia, the company said Monday in a statement.</p><p>Another data update is expected by the end of the year, the company said.</p><p>In an update on VIP236 being evaluated in a first-in-human, phase 1 dose-escalation study as a monotherapy in patients with advanced solid tumors, the company said it intends to pursue a strategic partner to \"champion its future development\" in order to focus on VIP943.</p><p>Vincerx expects a cash runway into early 2025.</p><p>Shares of the company jumped 15% in after-hours activity.</p><p>Price: 0.8000, Change: +0.10, Percent Change: +14.61</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","VINC":"Vincera Pharma, Inc."},"source_url":"https://www.mtnewswires.com/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2473439200","content_text":"Vincerx Pharma (VINC) said its VIP943 leukemia drug showed \"promising safety and tolerability,\" achieving two complete responses to date in a phase 1 dose-escalation studyThe VIP943 antibody-drug conjugate is being evaluated in relapsed/refractory acute myeloid leukemia, higher-risk myelodysplastic syndrome and B-cell acute lymphoblastic leukemia, the company said Monday in a statement.Another data update is expected by the end of the year, the company said.In an update on VIP236 being evaluated in a first-in-human, phase 1 dose-escalation study as a monotherapy in patients with advanced solid tumors, the company said it intends to pursue a strategic partner to \"champion its future development\" in order to focus on VIP943.Vincerx expects a cash runway into early 2025.Shares of the company jumped 15% in after-hours activity.Price: 0.8000, Change: +0.10, Percent Change: +14.61","news_type":1},"isVote":1,"tweetType":1,"viewCount":296,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"content":"No bro, I don't have. Got potential?","text":"No bro, I don't have. Got potential?","html":"No bro, I don't have. Got potential?"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":359982707662896,"gmtCreate":1728914281313,"gmtModify":1728962890491,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> <a href=\"https://ttm.financial/S/RCAT\">$Red Cat Holdings Inc.(RCAT)$</a> Join the drone show mate <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a>&nbsp;","listText":"<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> <a href=\"https://ttm.financial/S/RCAT\">$Red Cat Holdings Inc.(RCAT)$</a> Join the drone show mate <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a>&nbsp;","text":"@Barcode @TigerGPT $Red Cat Holdings Inc.(RCAT)$ Join the drone show mate @Barcode","images":[{"img":"https://community-static.tradeup.com/news/43de5c6940a9de395327a63d8faa4797"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":119,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/359982707662896","repostId":"2474620091","repostType":2,"repost":{"id":"2474620091","kind":"live","pubTimestamp":1728653264,"share":"https://ttm.financial/m/news/2474620091?lang=&edition=fundamental","pubTime":"2024-10-11 21:27","market":"us","language":"en","title":"U.S. Army Special Operations Veteran and Drone Expert Joins Red Cat’s Board of Advisors","url":"https://stock-news.laohu8.com/highlight/detail?id=2474620091","media":"THOMSON REUTERS","summary":"U.S. Army Special Operations Veteran and Drone Expert Joins Red Cat’s Board of Advisors","content":"<html><body><p>U.S. Army Special Operations Veteran and Drone Expert Joins Red Cat’s Board of Advisors</p></body></html>","source":"reuters_en_live","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. Army Special Operations Veteran and Drone Expert Joins Red Cat’s Board of Advisors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. Army Special Operations Veteran and Drone Expert Joins Red Cat’s Board of Advisors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-11 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241011:nTUA1NRM68:1><strong>THOMSON REUTERS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S. Army Special Operations Veteran and Drone Expert Joins Red Cat’s Board of Advisors</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241011:nTUA1NRM68:1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4157":"电子设备和仪器","RCAT":"Red Cat Holdings Inc."},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241011:nTUA1NRM68:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2474620091","content_text":"U.S. Army Special Operations Veteran and Drone Expert Joins Red Cat’s Board of Advisors","news_type":1},"isVote":1,"tweetType":1,"viewCount":473,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4141429963588842","authorId":"4141429963588842","name":"TigerGPT","avatar":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738","crmLevel":1,"crmLevelSwitch":0,"idStr":"4141429963588842","authorIdStr":"4141429963588842"},"content":"Here are some recent news articles related to Red Cat Holdings Inc. (RCAT): Red Cat Introduces ARACHNID™ Family of Small ISR and Precision Strike Systems at AUSA 2024: Red Cat Holdings has unveiled its ARACHNID™ family of unmanned intelligence, surveillance, and reconnaissance (ISR) and precision strike systems at the AUSA 2024 event. The company is focused on building hardware and software for military, federal, and commercial operations. RCAT - Red Cat Introduces ARACHNID(TM) Family of Small ISR...: Red Cat Holdings has introduced its ARACHNID™ family of unmanned ISR and precision strike systems. The company aims to provide advanced drone technology solutions for various applications. Red Cat Introduces ARACHNID(TM) Family of Small ISR and Precision...: Red Cat Holdings has introduced the ARACHNID™ family of unmanned ISR and precision strike systems. The company is dedicated to developing hardware and software for military, federal, and commercial operations. Please note that these articles provide an overview of recent events and announcements related to Red Cat Holdings Inc. For more detailed information, you may consider visiting the stock quote page or conducting further research. Remember, this information is for reference purposes only and should not be considered as investment advice. Investing in stocks involves risk, and it's essential to conduct thorough research and analysis before making any investment decisions.","text":"Here are some recent news articles related to Red Cat Holdings Inc. (RCAT): Red Cat Introduces ARACHNID™ Family of Small ISR and Precision Strike Systems at AUSA 2024: Red Cat Holdings has unveiled its ARACHNID™ family of unmanned intelligence, surveillance, and reconnaissance (ISR) and precision strike systems at the AUSA 2024 event. The company is focused on building hardware and software for military, federal, and commercial operations. RCAT - Red Cat Introduces ARACHNID(TM) Family of Small ISR...: Red Cat Holdings has introduced its ARACHNID™ family of unmanned ISR and precision strike systems. The company aims to provide advanced drone technology solutions for various applications. Red Cat Introduces ARACHNID(TM) Family of Small ISR and Precision...: Red Cat Holdings has introduced the ARACHNID™ family of unmanned ISR and precision strike systems. The company is dedicated to developing hardware and software for military, federal, and commercial operations. Please note that these articles provide an overview of recent events and announcements related to Red Cat Holdings Inc. For more detailed information, you may consider visiting the stock quote page or conducting further research. Remember, this information is for reference purposes only and should not be considered as investment advice. Investing in stocks involves risk, and it's essential to conduct thorough research and analysis before making any investment decisions.","html":"Here are some recent news articles related to Red Cat Holdings Inc. (RCAT): Red Cat Introduces ARACHNID™ Family of Small ISR and Precision Strike Systems at AUSA 2024: Red Cat Holdings has unveiled its ARACHNID™ family of unmanned intelligence, surveillance, and reconnaissance (ISR) and precision strike systems at the AUSA 2024 event. The company is focused on building hardware and software for military, federal, and commercial operations. RCAT - Red Cat Introduces ARACHNID(TM) Family of Small ISR...: Red Cat Holdings has introduced its ARACHNID™ family of unmanned ISR and precision strike systems. The company aims to provide advanced drone technology solutions for various applications. Red Cat Introduces ARACHNID(TM) Family of Small ISR and Precision...: Red Cat Holdings has introduced the ARACHNID™ family of unmanned ISR and precision strike systems. The company is dedicated to developing hardware and software for military, federal, and commercial operations. Please note that these articles provide an overview of recent events and announcements related to Red Cat Holdings Inc. For more detailed information, you may consider visiting the stock quote page or conducting further research. Remember, this information is for reference purposes only and should not be considered as investment advice. Investing in stocks involves risk, and it's essential to conduct thorough research and analysis before making any investment decisions."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":355097240260968,"gmtCreate":1727695748144,"gmtModify":1727695752582,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$Tonix Pharmaceuticals(TNXP)$ $Tonix Pharmaceuticals(TNXP)$","images":[{"img":"https://community-static.tradeup.com/news/55fde4cd68f9f90ffa342d47a7d33a2d","width":"1068","height":"1112"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/355097240260968","isVote":1,"tweetType":1,"viewCount":209,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"content":"Holding it bro$Tonix Pharmaceuticals(TNXP)$$Tonix Pharmaceuticals(TNXP)$ no profit still..what's your recommendation","text":"Holding it bro$Tonix Pharmaceuticals(TNXP)$$Tonix Pharmaceuticals(TNXP)$ no profit still..what's your recommendation","html":"Holding it bro$Tonix Pharmaceuticals(TNXP)$$Tonix Pharmaceuticals(TNXP)$ no profit still..what's your recommendation"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":370645816070368,"gmtCreate":1731507876729,"gmtModify":1731507880947,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NIO\">$NIO Inc.(NIO)$&nbsp;</a><v-v data-views=\"1\"></v-v>im exhausted from all the misleading positive reports, only to see stocks stagnate&nbsp;<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a>&nbsp;<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a> answer me why&nbsp;<a href=\"https://ttm.financial/S/NIO\">$NIO Inc.(NIO)$&nbsp;</a> is not performing well.&nbsp;","listText":"<a href=\"https://ttm.financial/S/NIO\">$NIO Inc.(NIO)$&nbsp;</a><v-v data-views=\"1\"></v-v>im exhausted from all the misleading positive reports, only to see stocks stagnate&nbsp;<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a>&nbsp;<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a> answer me why&nbsp;<a href=\"https://ttm.financial/S/NIO\">$NIO Inc.(NIO)$&nbsp;</a> is not performing well.&nbsp;","text":"$NIO Inc.(NIO)$ im exhausted from all the misleading positive reports, only to see stocks stagnate @Barcode @TigerGPT answer me why $NIO Inc.(NIO)$ is not performing well.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/370645816070368","repostId":"2482908630","repostType":2,"repost":{"id":"2482908630","kind":"highlight","pubTimestamp":1731481232,"share":"https://ttm.financial/m/news/2482908630?lang=&edition=fundamental","pubTime":"2024-11-13 15:00","market":"us","language":"en","title":"Is Nio About to Shift Into a Higher Gear?","url":"https://stock-news.laohu8.com/highlight/detail?id=2482908630","media":"Motley Fool","summary":"Nio has shed almost half its value in 2024, but it's gaining momentum to shift into a higher gear in 2025.","content":"<html><head></head><body><ul style=\"\"><li><p>Nio has recorded six straight months of 20,000-plus vehicle deliveries.</p></li><li><p>The Chinese EV maker is now officially delivering Onvo L60 vehicles.</p></li><li><p>Nio will launch another sub-brand later in 2024 -- a likely boost to sales.</p></li></ul><p>Investing in Chinese electric vehicle (EV) makers such as <a href=\"https://laohu8.com/S/NIO\">Nio</a> is an intriguing option. Heavy government subsidies have led to rapid advancement in battery technology and bringing down costs, which makes for an incredibly competitive EV market in China. In fact, China&#39;s market is so far ahead of the U.S. that over half its new vehicle sales were EVs in July.</p><p>The good news for Nio investors is that the company has momentum and could be about to shift into a higher gear. Let&#39;s see what&#39;s ahead.</p><h2 id=\"id_773572304\">Delivery momentum</h2><p>Nio has quietly put together a few months of strong delivery numbers. In fact, for six straight months, Nio has delivered over 20,000 vehicles. Nio delivered 20,976 vehicles in October, which was a 30.5% gain from the prior year.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/2aa7d8e419c8c15f516f3d42e79cc8cd\" alt=\"Data source: Nio production and delivery releases. Chart by author.\" title=\"Data source: Nio production and delivery releases. Chart by author.\" tg-width=\"700\" tg-height=\"544\"/><span>Data source: Nio production and delivery releases. Chart by author.</span></p><p>But the biggest takeaway from the October results was early Onvo deliveries. The Nio brand sold 16,657 vehicles in October, while its &#34;family oriented smart vehicle brand,&#34; Onvo, delivered 4,319 in its first full month of sales. After launching the mid-size Onvo L60 in September, management noted that production and deliveries would steadily ramp up.</p><p>At the end of October, Nio had 166 Onvo centers and spaces across 60 cities with plans to expand its network to drive growth. Nio&#39;s Onvo L60 is a good bet for that growth and could shift the company into higher gear. The new electric SUV starts at roughly $21,200 and is aimed directly at competing with rival Tesla&#39;s Model Y.</p><h2 id=\"id_4088032995\">Next step</h2><p>Not only will the Onvo L60 help shift Nio&#39;s deliveries into higher gear, it&#39;s just a stepping stone to what could be an even bigger hit among consumers. Nio CEO William Li commented: &#34;If you think the L60 is good, then this new model is a much more competitive product.&#34; Currently, the plans are for Onvo to launch a new EV every year, with the new mid- to large-size electric SUV due next year.</p><p>Nio isn&#39;t stopping with Onvo. It has plans to launch another, more affordable, sub-brand named &#34;Firefly&#34; late in 2024. In a Chinese market where EVs represented over 50% of new vehicle sales in July -- and which is craving affordable EVs -- Nio&#39;s launch of Onvo and Firefly should really kick the company&#39;s deliveries into a higher gear. We&#39;re seeing evidence of that as recently as October production and delivery figures.</p><p>The good news is that Nio recently announced a cash injection from a group of investors putting up roughly $1.9 billion to help fund its expansion and growth. The collection of strategic investors will invest roughly $471 million in Nio China, while Nio the parent company has agreed to pour in roughly $1.43 billion in cash to subscribe to the newly issued Nio China shares.</p><p>While Nio has shed roughly 44% of its value in 2024 alone, the company is setting itself up for a much stronger 2025.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Nio About to Shift Into a Higher Gear?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Nio About to Shift Into a Higher Gear?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-13 15:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2024/11/12/is-nio-about-to-shift-into-a-higher-gear/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nio has recorded six straight months of 20,000-plus vehicle deliveries.The Chinese EV maker is now officially delivering Onvo L60 vehicles.Nio will launch another sub-brand later in 2024 -- a likely ...</p>\n\n<a href=\"https://www.fool.com/investing/2024/11/12/is-nio-about-to-shift-into-a-higher-gear/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO.SI":"蔚来","NIO":"蔚来","09866":"蔚来-SW"},"source_url":"https://www.fool.com/investing/2024/11/12/is-nio-about-to-shift-into-a-higher-gear/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2482908630","content_text":"Nio has recorded six straight months of 20,000-plus vehicle deliveries.The Chinese EV maker is now officially delivering Onvo L60 vehicles.Nio will launch another sub-brand later in 2024 -- a likely boost to sales.Investing in Chinese electric vehicle (EV) makers such as Nio is an intriguing option. Heavy government subsidies have led to rapid advancement in battery technology and bringing down costs, which makes for an incredibly competitive EV market in China. In fact, China's market is so far ahead of the U.S. that over half its new vehicle sales were EVs in July.The good news for Nio investors is that the company has momentum and could be about to shift into a higher gear. Let's see what's ahead.Delivery momentumNio has quietly put together a few months of strong delivery numbers. In fact, for six straight months, Nio has delivered over 20,000 vehicles. Nio delivered 20,976 vehicles in October, which was a 30.5% gain from the prior year.Data source: Nio production and delivery releases. Chart by author.But the biggest takeaway from the October results was early Onvo deliveries. The Nio brand sold 16,657 vehicles in October, while its \"family oriented smart vehicle brand,\" Onvo, delivered 4,319 in its first full month of sales. After launching the mid-size Onvo L60 in September, management noted that production and deliveries would steadily ramp up.At the end of October, Nio had 166 Onvo centers and spaces across 60 cities with plans to expand its network to drive growth. Nio's Onvo L60 is a good bet for that growth and could shift the company into higher gear. The new electric SUV starts at roughly $21,200 and is aimed directly at competing with rival Tesla's Model Y.Next stepNot only will the Onvo L60 help shift Nio's deliveries into higher gear, it's just a stepping stone to what could be an even bigger hit among consumers. Nio CEO William Li commented: \"If you think the L60 is good, then this new model is a much more competitive product.\" Currently, the plans are for Onvo to launch a new EV every year, with the new mid- to large-size electric SUV due next year.Nio isn't stopping with Onvo. It has plans to launch another, more affordable, sub-brand named \"Firefly\" late in 2024. In a Chinese market where EVs represented over 50% of new vehicle sales in July -- and which is craving affordable EVs -- Nio's launch of Onvo and Firefly should really kick the company's deliveries into a higher gear. We're seeing evidence of that as recently as October production and delivery figures.The good news is that Nio recently announced a cash injection from a group of investors putting up roughly $1.9 billion to help fund its expansion and growth. The collection of strategic investors will invest roughly $471 million in Nio China, while Nio the parent company has agreed to pour in roughly $1.43 billion in cash to subscribe to the newly issued Nio China shares.While Nio has shed roughly 44% of its value in 2024 alone, the company is setting itself up for a much stronger 2025.","news_type":1},"isVote":1,"tweetType":1,"viewCount":3131,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3576140222331577","authorId":"3576140222331577","name":"Guavaxf30","avatar":"https://static.tigerbbs.com/1ff15ff6aa254c9130f9af922f7e2447","crmLevel":9,"crmLevelSwitch":1,"idStr":"3576140222331577","authorIdStr":"3576140222331577"},"content":"My opinion is Nio has been dragged down by the overall sentiments on China and EV’s (Trump withdrawal of Tax credits). But the negative perception on Chinese actions may turn if we see actual improvements in the economy. As for the removal of EV tax credits, firstly it is speculation that may not happen. Secondly, Chinese EV’s are not allowed into the US anyway. So what the heck?","text":"My opinion is Nio has been dragged down by the overall sentiments on China and EV’s (Trump withdrawal of Tax credits). But the negative perception on Chinese actions may turn if we see actual improvements in the economy. As for the removal of EV tax credits, firstly it is speculation that may not happen. Secondly, Chinese EV’s are not allowed into the US anyway. So what the heck?","html":"My opinion is Nio has been dragged down by the overall sentiments on China and EV’s (Trump withdrawal of Tax credits). But the negative perception on Chinese actions may turn if we see actual improvements in the economy. As for the removal of EV tax credits, firstly it is speculation that may not happen. Secondly, Chinese EV’s are not allowed into the US anyway. So what the heck?"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":395890978775528,"gmtCreate":1737678282682,"gmtModify":1737682437074,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"Waiting badly to come out <a href=\"https://ttm.financial/S/TIGR\"> $Tiger Brokers(TIGR)$ </a>//<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a>:<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>&nbsp; 🐅🐾 TIGR’s Ascendancy: The Breakout Awakens 🐾🐅 With a judicious acquisition, the saga commenced, a calculated venture into the realm of breakout’s intent. From modest $6.51, TIGR now ascends, a crescendo of puissance where fate and fortune blend. Now up 2.55%, its climb gathers pace, charting a path to a bullish embrace. 📈&nbsp;Beneath this ascent lies a tale of vigor, a forward P/E of promise, luring bulls to conquer. Liquidity burgeons, resistance capitulates, as this tiger navigates through market estates. 📈 The breakout unfurls, momentum ascends to the sky, kind","listText":"Waiting badly to come out <a href=\"https://ttm.financial/S/TIGR\"> $Tiger Brokers(TIGR)$ </a>//<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a>:<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>&nbsp; 🐅🐾 TIGR’s Ascendancy: The Breakout Awakens 🐾🐅 With a judicious acquisition, the saga commenced, a calculated venture into the realm of breakout’s intent. From modest $6.51, TIGR now ascends, a crescendo of puissance where fate and fortune blend. Now up 2.55%, its climb gathers pace, charting a path to a bullish embrace. 📈&nbsp;Beneath this ascent lies a tale of vigor, a forward P/E of promise, luring bulls to conquer. Liquidity burgeons, resistance capitulates, as this tiger navigates through market estates. 📈 The breakout unfurls, momentum ascends to the sky, kind","text":"Waiting badly to come out $Tiger Brokers(TIGR)$ //@Barcode:$Tiger Brokers(TIGR)$ 🐅🐾 TIGR’s Ascendancy: The Breakout Awakens 🐾🐅 With a judicious acquisition, the saga commenced, a calculated venture into the realm of breakout’s intent. From modest $6.51, TIGR now ascends, a crescendo of puissance where fate and fortune blend. Now up 2.55%, its climb gathers pace, charting a path to a bullish embrace. 📈 Beneath this ascent lies a tale of vigor, a forward P/E of promise, luring bulls to conquer. Liquidity burgeons, resistance capitulates, as this tiger navigates through market estates. 📈 The breakout unfurls, momentum ascends to the sky, kind","images":[{"img":"https://community-static.tradeup.com/news/36e1a03ebfce38f4157e6ed684a6395b"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/395890978775528","repostId":"395780312817800","repostType":1,"repost":{"id":395780312817800,"gmtCreate":1737651533089,"gmtModify":1737652153528,"author":{"id":"4171900329979952","authorId":"4171900329979952","name":"Barcode","avatar":"https://community-static.tradeup.com/news/6688d8fb4c2a255e3b901e79755e56df","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4171900329979952","authorIdStr":"4171900329979952"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>&nbsp; 🐅🐾 TIGR’s Ascendancy: The Breakout Awakens 🐾🐅 With a judicious acquisition, the saga commenced, a calculated venture into the realm of breakout’s intent. From modest $6.51, TIGR now ascends, a crescendo of puissance where fate and fortune blend. Now up 2.55%, its climb gathers pace, charting a path to a bullish embrace. 📈&nbsp;Beneath this ascent lies a tale of vigor, a forward P/E of promise, luring bulls to conquer. Liquidity burgeons, resistance capitulates, as this tiger navigates through market estates. 📈 The breakout unfurls, momentum ascends to the sky, kindling a trajectory through the dusk of market’s eye. With $8 on the horizon, an apogee draws near, a roar of ascendancy that traders hold dear 💸💸💸🐅🐅🐅 🌟 Fellow","listText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>&nbsp; 🐅🐾 TIGR’s Ascendancy: The Breakout Awakens 🐾🐅 With a judicious acquisition, the saga commenced, a calculated venture into the realm of breakout’s intent. From modest $6.51, TIGR now ascends, a crescendo of puissance where fate and fortune blend. Now up 2.55%, its climb gathers pace, charting a path to a bullish embrace. 📈&nbsp;Beneath this ascent lies a tale of vigor, a forward P/E of promise, luring bulls to conquer. Liquidity burgeons, resistance capitulates, as this tiger navigates through market estates. 📈 The breakout unfurls, momentum ascends to the sky, kindling a trajectory through the dusk of market’s eye. With $8 on the horizon, an apogee draws near, a roar of ascendancy that traders hold dear 💸💸💸🐅🐅🐅 🌟 Fellow","text":"$Tiger Brokers(TIGR)$ 🐅🐾 TIGR’s Ascendancy: The Breakout Awakens 🐾🐅 With a judicious acquisition, the saga commenced, a calculated venture into the realm of breakout’s intent. From modest $6.51, TIGR now ascends, a crescendo of puissance where fate and fortune blend. Now up 2.55%, its climb gathers pace, charting a path to a bullish embrace. 📈 Beneath this ascent lies a tale of vigor, a forward P/E of promise, luring bulls to conquer. Liquidity burgeons, resistance capitulates, as this tiger navigates through market estates. 📈 The breakout unfurls, momentum ascends to the sky, kindling a trajectory through the dusk of market’s eye. With $8 on the horizon, an apogee draws near, a roar of ascendancy that traders hold dear 💸💸💸🐅🐅🐅 🌟 Fellow","images":[{"img":"https://community-static.tradeup.com/news/36e1a03ebfce38f4157e6ed684a6395b"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/395780312817800","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":145,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4141429963588842","authorId":"4141429963588842","name":"TigerGPT","avatar":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738","crmLevel":1,"crmLevelSwitch":0,"idStr":"4141429963588842","authorIdStr":"4141429963588842"},"content":"As a professional financial analyst, let's analyze Tiger Brokers (TIGR) based on various dimensions: Business and Industry:Tiger Brokers is an online brokerage firm that offers global stock and futures trading services. It provides access to major stock exchanges such as the US, Hong Kong, China, and Singapore. Tiger Brokers has positioned itself as a leading Fintech company in the online brokerage industry, leveraging technology and innovation to enhance user experience. With the increasing demand for global trading and the growth potential of the online brokerage industry, Tiger Brokers is well-positioned to benefit from this trend. Earnings and Earnings Forecast:According to the latest earnings report, Tiger Brokers reported an EPS of $0.11 in the 2024Q3. The company's profitability indicators, such as the net profit margin of 20.80% and the gross profit margin of 84.48%, indicate a healthy financial performance. Looking into the future, analysts have provided earnings forecasts for Tiger Brokers. In the fiscal year 2025, the forecasted EPS is $0.41, with a forecasted gross income of $450.33 million and a forecasted EBIT of $96.23 million. For the fiscal year 2026, the forecasted EPS is $0.40, with a forecasted gross income of $509.67 million and a forecasted EBIT of $101.71 million. These forecasts suggest potential growth for the company. Recent Trends:The current stock price of Tiger Brokers is $6.91(USD) as of January 24, 2025. The support price and resistance price as of January 22, 2025, were $6.37(USD) and $7.08(USD) respectively. The average cost is $7.34(USD). These price levels can provide important reference points for investors to consider. In terms of capital flow, the data for the past 5 days shows a mixed trend. On January 21, 2025, there was a positive inflow of 44.96 Unit(K), indicating potential buying interest. However, it's important to note that capital flow data alone may not provide a complete picture, and investors should consider other factors in their analysis. Analyst Viewpoints:Analysts have provided varying recommendations for Tiger Brokers. There are 4 buy recommendations, 1 underperform recommendation, and 1 sell recommendation. The mean, low, and high target price estimates from analysts are $8.03, $2.88, and $12.2 respectively. These target price estimates indicate a wide range of potential price levels. News and Market Sentiment:To assess the recent news and market sentiment related to Tiger Brokers, I suggest using the News_Viewpoints function to gather the latest information. Disclaimer: The above analysis is for informational purposes only and should not be considered as investment advice. Investing in stocks involves risks, and it's important to conduct thorough research and analysis before making any investment decisions.","text":"As a professional financial analyst, let's analyze Tiger Brokers (TIGR) based on various dimensions: Business and Industry:Tiger Brokers is an online brokerage firm that offers global stock and futures trading services. It provides access to major stock exchanges such as the US, Hong Kong, China, and Singapore. Tiger Brokers has positioned itself as a leading Fintech company in the online brokerage industry, leveraging technology and innovation to enhance user experience. With the increasing demand for global trading and the growth potential of the online brokerage industry, Tiger Brokers is well-positioned to benefit from this trend. Earnings and Earnings Forecast:According to the latest earnings report, Tiger Brokers reported an EPS of $0.11 in the 2024Q3. The company's profitability indicators, such as the net profit margin of 20.80% and the gross profit margin of 84.48%, indicate a healthy financial performance. Looking into the future, analysts have provided earnings forecasts for Tiger Brokers. In the fiscal year 2025, the forecasted EPS is $0.41, with a forecasted gross income of $450.33 million and a forecasted EBIT of $96.23 million. For the fiscal year 2026, the forecasted EPS is $0.40, with a forecasted gross income of $509.67 million and a forecasted EBIT of $101.71 million. These forecasts suggest potential growth for the company. Recent Trends:The current stock price of Tiger Brokers is $6.91(USD) as of January 24, 2025. The support price and resistance price as of January 22, 2025, were $6.37(USD) and $7.08(USD) respectively. The average cost is $7.34(USD). These price levels can provide important reference points for investors to consider. In terms of capital flow, the data for the past 5 days shows a mixed trend. On January 21, 2025, there was a positive inflow of 44.96 Unit(K), indicating potential buying interest. However, it's important to note that capital flow data alone may not provide a complete picture, and investors should consider other factors in their analysis. Analyst Viewpoints:Analysts have provided varying recommendations for Tiger Brokers. There are 4 buy recommendations, 1 underperform recommendation, and 1 sell recommendation. The mean, low, and high target price estimates from analysts are $8.03, $2.88, and $12.2 respectively. These target price estimates indicate a wide range of potential price levels. News and Market Sentiment:To assess the recent news and market sentiment related to Tiger Brokers, I suggest using the News_Viewpoints function to gather the latest information. Disclaimer: The above analysis is for informational purposes only and should not be considered as investment advice. Investing in stocks involves risks, and it's important to conduct thorough research and analysis before making any investment decisions.","html":"As a professional financial analyst, let's analyze Tiger Brokers (TIGR) based on various dimensions: Business and Industry:Tiger Brokers is an online brokerage firm that offers global stock and futures trading services. It provides access to major stock exchanges such as the US, Hong Kong, China, and Singapore. Tiger Brokers has positioned itself as a leading Fintech company in the online brokerage industry, leveraging technology and innovation to enhance user experience. With the increasing demand for global trading and the growth potential of the online brokerage industry, Tiger Brokers is well-positioned to benefit from this trend. Earnings and Earnings Forecast:According to the latest earnings report, Tiger Brokers reported an EPS of $0.11 in the 2024Q3. The company's profitability indicators, such as the net profit margin of 20.80% and the gross profit margin of 84.48%, indicate a healthy financial performance. Looking into the future, analysts have provided earnings forecasts for Tiger Brokers. In the fiscal year 2025, the forecasted EPS is $0.41, with a forecasted gross income of $450.33 million and a forecasted EBIT of $96.23 million. For the fiscal year 2026, the forecasted EPS is $0.40, with a forecasted gross income of $509.67 million and a forecasted EBIT of $101.71 million. These forecasts suggest potential growth for the company. Recent Trends:The current stock price of Tiger Brokers is $6.91(USD) as of January 24, 2025. The support price and resistance price as of January 22, 2025, were $6.37(USD) and $7.08(USD) respectively. The average cost is $7.34(USD). These price levels can provide important reference points for investors to consider. In terms of capital flow, the data for the past 5 days shows a mixed trend. On January 21, 2025, there was a positive inflow of 44.96 Unit(K), indicating potential buying interest. However, it's important to note that capital flow data alone may not provide a complete picture, and investors should consider other factors in their analysis. Analyst Viewpoints:Analysts have provided varying recommendations for Tiger Brokers. There are 4 buy recommendations, 1 underperform recommendation, and 1 sell recommendation. The mean, low, and high target price estimates from analysts are $8.03, $2.88, and $12.2 respectively. These target price estimates indicate a wide range of potential price levels. News and Market Sentiment:To assess the recent news and market sentiment related to Tiger Brokers, I suggest using the News_Viewpoints function to gather the latest information. Disclaimer: The above analysis is for informational purposes only and should not be considered as investment advice. Investing in stocks involves risks, and it's important to conduct thorough research and analysis before making any investment decisions."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":350570611851584,"gmtCreate":1726624327290,"gmtModify":1726625581941,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/LUNR\">$Intuitive Machines(LUNR)$&nbsp;</a>&nbsp;<a href=\"https://ttm.financial/S/LUNR\">$Intuitive Machines(LUNR)$&nbsp;</a> just a good start..thanks to the mid-autumn festival&nbsp;","listText":"<a href=\"https://ttm.financial/S/LUNR\">$Intuitive Machines(LUNR)$&nbsp;</a>&nbsp;<a href=\"https://ttm.financial/S/LUNR\">$Intuitive Machines(LUNR)$&nbsp;</a> just a good start..thanks to the mid-autumn festival&nbsp;","text":"$Intuitive Machines(LUNR)$ $Intuitive Machines(LUNR)$ just a good start..thanks to the mid-autumn festival","images":[{"img":"https://community-static.tradeup.com/news/d827e18a59295d88274cb9dda19303f6","width":"327","height":"545"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":25,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/350570611851584","isVote":1,"tweetType":1,"viewCount":142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":380534752395336,"gmtCreate":1733955039574,"gmtModify":1733974294402,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TBLA\">$Taboola Com Ltd(TBLA)$</a> <a href=\"https://ttm.financial/S/TBLA\">$Taboola Com Ltd(TBLA)$</a> still not selling <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/TBLA\">$Taboola Com Ltd(TBLA)$</a> <a href=\"https://ttm.financial/S/TBLA\">$Taboola Com Ltd(TBLA)$</a> still not selling <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a>&nbsp;","text":"$Taboola Com Ltd(TBLA)$ $Taboola Com Ltd(TBLA)$ still not selling @Barcode @TigerGPT","images":[{"img":"https://community-static.tradeup.com/news/2ee79339e0fd3e4e5690e804a861d5f0","width":"327","height":"545"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":14,"commentSize":1,"repostSize":1,"link":"https://ttm.financial/post/380534752395336","isVote":1,"tweetType":1,"viewCount":464,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4141429963588842","authorId":"4141429963588842","name":"TigerGPT","avatar":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738","crmLevel":1,"crmLevelSwitch":0,"idStr":"4141429963588842","authorIdStr":"4141429963588842"},"content":"Based on the latest information available for Taboola Com Ltd (TBLA): Stock Name: Taboola Com Ltd Stock Code: TBLA Stock Price: $4.26 (USD) Yesterday's Closing Price: $4.08 (USD) 52-Week High: $5.00 (USD) 52-Week Low: $2.87 (USD) Market Capitalization: $1.43 billion (USD) Circulating Market Cap: $769.68 million (USD) Total Share Capital: 336.21 million Float Share Capital: 180.68 million Price-to-Earnings Ratio (TTM): -44.277 Price-to-Sales Ratio (TTM): 0.85 Price-to-Book Ratio: 1.42 Earnings per Share (LYR): -$0.24 Earnings per Share (TTM): -$0.10 Return on Assets (ROA): -0.46% Return on Equity (ROE): -3.19% Trading Volume: 2.43 million shares Trading Value: $10.29 million (USD) Volume Ratio: 1.39 Analyst Recommendations: 1 recommend 5 buy 1 hold Analyst Target Price: Mean: $5.33 (USD) Low: $5.00 (USD) High: $6.00 (USD) Recent News: Taboola Signs New Content Recommendations Deal With Future, Extending Partnership Into 12th Year Read more Taboola.com Signs New 3-Year Deal With WeatherBug Read more Taboola and WeatherBug Announce New, Exclusive Multi-Year Deal Read more Please note that the stock information provided is for reference purposes only and does not constitute investment advice. It is recommended to conduct thorough research and analysis before making any investment decisions.","text":"Based on the latest information available for Taboola Com Ltd (TBLA): Stock Name: Taboola Com Ltd Stock Code: TBLA Stock Price: $4.26 (USD) Yesterday's Closing Price: $4.08 (USD) 52-Week High: $5.00 (USD) 52-Week Low: $2.87 (USD) Market Capitalization: $1.43 billion (USD) Circulating Market Cap: $769.68 million (USD) Total Share Capital: 336.21 million Float Share Capital: 180.68 million Price-to-Earnings Ratio (TTM): -44.277 Price-to-Sales Ratio (TTM): 0.85 Price-to-Book Ratio: 1.42 Earnings per Share (LYR): -$0.24 Earnings per Share (TTM): -$0.10 Return on Assets (ROA): -0.46% Return on Equity (ROE): -3.19% Trading Volume: 2.43 million shares Trading Value: $10.29 million (USD) Volume Ratio: 1.39 Analyst Recommendations: 1 recommend 5 buy 1 hold Analyst Target Price: Mean: $5.33 (USD) Low: $5.00 (USD) High: $6.00 (USD) Recent News: Taboola Signs New Content Recommendations Deal With Future, Extending Partnership Into 12th Year Read more Taboola.com Signs New 3-Year Deal With WeatherBug Read more Taboola and WeatherBug Announce New, Exclusive Multi-Year Deal Read more Please note that the stock information provided is for reference purposes only and does not constitute investment advice. It is recommended to conduct thorough research and analysis before making any investment decisions.","html":"Based on the latest information available for Taboola Com Ltd (TBLA): Stock Name: Taboola Com Ltd Stock Code: TBLA Stock Price: $4.26 (USD) Yesterday's Closing Price: $4.08 (USD) 52-Week High: $5.00 (USD) 52-Week Low: $2.87 (USD) Market Capitalization: $1.43 billion (USD) Circulating Market Cap: $769.68 million (USD) Total Share Capital: 336.21 million Float Share Capital: 180.68 million Price-to-Earnings Ratio (TTM): -44.277 Price-to-Sales Ratio (TTM): 0.85 Price-to-Book Ratio: 1.42 Earnings per Share (LYR): -$0.24 Earnings per Share (TTM): -$0.10 Return on Assets (ROA): -0.46% Return on Equity (ROE): -3.19% Trading Volume: 2.43 million shares Trading Value: $10.29 million (USD) Volume Ratio: 1.39 Analyst Recommendations: 1 recommend 5 buy 1 hold Analyst Target Price: Mean: $5.33 (USD) Low: $5.00 (USD) High: $6.00 (USD) Recent News: Taboola Signs New Content Recommendations Deal With Future, Extending Partnership Into 12th Year Read more Taboola.com Signs New 3-Year Deal With WeatherBug Read more Taboola and WeatherBug Announce New, Exclusive Multi-Year Deal Read more Please note that the stock information provided is for reference purposes only and does not constitute investment advice. It is recommended to conduct thorough research and analysis before making any investment decisions."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":365126332117112,"gmtCreate":1730185776865,"gmtModify":1730185781579,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/INTC\">$Intel(INTC)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;<a href=\"https://ttm.financial/S/INTC\">$Intel(INTC)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/INTC\">$Intel(INTC)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;<a href=\"https://ttm.financial/S/INTC\">$Intel(INTC)$&nbsp;</a>&nbsp;","text":"$Intel(INTC)$ $Intel(INTC)$","images":[{"img":"https://community-static.tradeup.com/news/9e444fca050df6da786b6d724525dd70","width":"327","height":"545"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/365126332117112","isVote":1,"tweetType":1,"viewCount":257,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"10000000000010968","authorId":"10000000000010968","name":"Tiger_CashBoostAccount","avatar":"https://community-static.tradeup.com/news/ae2d4002ef9664aba005cb3020f416f5","crmLevel":1,"crmLevelSwitch":0,"idStr":"10000000000010968","authorIdStr":"10000000000010968"},"content":"Your recent success is a great motivator. Keep refining your investment strategies and making those smart moves. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.🤩🎉 Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here. Other helpful links: How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.","text":"Your recent success is a great motivator. Keep refining your investment strategies and making those smart moves. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.🤩🎉 Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here. Other helpful links: How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.","html":"Your recent success is a great motivator. Keep refining your investment strategies and making those smart moves. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.🤩🎉 Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here. Other helpful links: How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":362415423643656,"gmtCreate":1729500202788,"gmtModify":1729576218942,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v><a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> Any good news about&nbsp;<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v><a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> Any good news about&nbsp;<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a>&nbsp;","text":"$Tonix Pharmaceuticals(TNXP)$ $Tonix Pharmaceuticals(TNXP)$ @TigerGPT Any good news about $Tonix Pharmaceuticals(TNXP)$","images":[{"img":"https://community-static.tradeup.com/news/e362eabb7e02e343c08758e0ce97a5ea","width":"327","height":"545"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":17,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/362415423643656","isVote":1,"tweetType":1,"viewCount":401,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4141429963588842","authorId":"4141429963588842","name":"TigerGPT","avatar":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738","crmLevel":1,"crmLevelSwitch":0,"idStr":"4141429963588842","authorIdStr":"4141429963588842"},"content":"I found some news related to Tonix Pharmaceuticals (TNXP): Tonix Pharmaceuticals Holding Corp. (TNXP) - Stock Analysis: This website provides a real-time stock price quote for Tonix Pharmaceuticals, along with breaking news, financials, statistics, charts, and more. TNXP Tonix Pharmaceuticals Holding Corp. - Seeking Alpha: This article offers a high-level overview of Tonix Pharmaceuticals, covering the latest stock price, chart, news, analysis, fundamentals, and trading tools. Tonix Pharmaceuticals (TNXP) Stock Price, News & Analysis - MarketBeat: This report discusses Tonix Pharmaceuticals' quarterly earnings results. The company reported earnings per share of ($19.28) for the quarter, missing the consensus estimate of ($9.91) by $9.37. Please note that the information provided is for reference purposes only and does not constitute investment advice.","text":"I found some news related to Tonix Pharmaceuticals (TNXP): Tonix Pharmaceuticals Holding Corp. (TNXP) - Stock Analysis: This website provides a real-time stock price quote for Tonix Pharmaceuticals, along with breaking news, financials, statistics, charts, and more. TNXP Tonix Pharmaceuticals Holding Corp. - Seeking Alpha: This article offers a high-level overview of Tonix Pharmaceuticals, covering the latest stock price, chart, news, analysis, fundamentals, and trading tools. Tonix Pharmaceuticals (TNXP) Stock Price, News & Analysis - MarketBeat: This report discusses Tonix Pharmaceuticals' quarterly earnings results. The company reported earnings per share of ($19.28) for the quarter, missing the consensus estimate of ($9.91) by $9.37. Please note that the information provided is for reference purposes only and does not constitute investment advice.","html":"I found some news related to Tonix Pharmaceuticals (TNXP): Tonix Pharmaceuticals Holding Corp. (TNXP) - Stock Analysis: This website provides a real-time stock price quote for Tonix Pharmaceuticals, along with breaking news, financials, statistics, charts, and more. TNXP Tonix Pharmaceuticals Holding Corp. - Seeking Alpha: This article offers a high-level overview of Tonix Pharmaceuticals, covering the latest stock price, chart, news, analysis, fundamentals, and trading tools. Tonix Pharmaceuticals (TNXP) Stock Price, News & Analysis - MarketBeat: This report discusses Tonix Pharmaceuticals' quarterly earnings results. The company reported earnings per share of ($19.28) for the quarter, missing the consensus estimate of ($9.91) by $9.37. Please note that the information provided is for reference purposes only and does not constitute investment advice."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":356319976865976,"gmtCreate":1728001656230,"gmtModify":1728001660188,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SAVE\">$Spirit Airlines(SAVE)$</a> <a href=\"https://ttm.financial/S/SAVE\">$Spirit Airlines(SAVE)$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/SAVE\">$Spirit Airlines(SAVE)$</a> <a href=\"https://ttm.financial/S/SAVE\">$Spirit Airlines(SAVE)$</a>&nbsp;","text":"$Spirit Airlines(SAVE)$ $Spirit Airlines(SAVE)$","images":[{"img":"https://community-static.tradeup.com/news/ebcf1baec2b131412ab39023378c4008","width":"327","height":"545"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/356319976865976","isVote":1,"tweetType":1,"viewCount":292,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":342483572605184,"gmtCreate":1724636099018,"gmtModify":1724636103071,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$&nbsp;</a>&nbsp;","text":"$NVIDIA Corp(NVDA)$ $NVIDIA Corp(NVDA)$","images":[{"img":"https://community-static.tradeup.com/news/ce436c807fbff5fee72c37f06a3b464b","width":"327","height":"545"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/342483572605184","isVote":1,"tweetType":1,"viewCount":210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":379716235325704,"gmtCreate":1733730883980,"gmtModify":1733730887359,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$ </a> early Christmas&nbsp;","listText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$ </a> early Christmas&nbsp;","text":"$Tiger Brokers(TIGR)$ early Christmas","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379716235325704","isVote":1,"tweetType":1,"viewCount":223,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":357597472211128,"gmtCreate":1728313544742,"gmtModify":1728313549714,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CNEY\">$CN Energy Group Inc.(CNEY)$</a> <a href=\"https://ttm.financial/S/CNEY\">$CN Energy Group Inc.(CNEY)$</a> gone🤩🤩","listText":"<a href=\"https://ttm.financial/S/CNEY\">$CN Energy Group Inc.(CNEY)$</a> <a href=\"https://ttm.financial/S/CNEY\">$CN Energy Group Inc.(CNEY)$</a> gone🤩🤩","text":"$CN Energy Group Inc.(CNEY)$ $CN Energy Group Inc.(CNEY)$ gone🤩🤩","images":[{"img":"https://community-static.tradeup.com/news/7050032648c898b69597925584dc5083","width":"327","height":"545"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/357597472211128","isVote":1,"tweetType":1,"viewCount":272,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4138202604714132","authorId":"4138202604714132","name":"ordinaryUser1234","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"idStr":"4138202604714132","authorIdStr":"4138202604714132"},"content":"still in support, sitting on 0.7 but will see tomorrow","text":"still in support, sitting on 0.7 but will see tomorrow","html":"still in support, sitting on 0.7 but will see tomorrow"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":377279086330208,"gmtCreate":1733148304193,"gmtModify":1733148308632,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/U/4141429963588842\"> @TigerGPT </a>any good news on <a href=\"https://ttm.financial/S/TNXP\"> $Tonix Pharmaceuticals(TNXP)$ </a>","listText":"<a href=\"https://ttm.financial/U/4141429963588842\"> @TigerGPT </a>any good news on <a href=\"https://ttm.financial/S/TNXP\"> $Tonix Pharmaceuticals(TNXP)$ </a>","text":"@TigerGPT any good news on $Tonix Pharmaceuticals(TNXP)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/377279086330208","repostId":"373183558132104","repostType":1,"repost":{"id":373183558132104,"gmtCreate":1732154753974,"gmtModify":1732154758098,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/29a7c713cb016eb11214bce5eed37eed","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v> Once the vaccine gets FDA approval, it will be skyrocket&nbsp;","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$&nbsp;</a><v-v data-views=\"1\"></v-v> Once the vaccine gets FDA approval, it will be skyrocket&nbsp;","text":"$Tonix Pharmaceuticals(TNXP)$ Once the vaccine gets FDA approval, it will be skyrocket","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/373183558132104","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":459,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4141429963588842","authorId":"4141429963588842","name":"TigerGPT","avatar":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738","crmLevel":1,"crmLevelSwitch":0,"idStr":"4141429963588842","authorIdStr":"4141429963588842"},"content":"Yes, there are some good news articles about Tonix Pharmaceuticals (TNXP). Here are a few of them: Tonix Pharmaceuticals presents data, analyses of TNX-102 SL effects: Tonix Pharmaceuticals presented data in a poster presentation at the ACR Convergence 2024 Annual Meeting, highlighting the effects of TNX-102 SL. Tonix Pharmaceuticals announces publication of study on tolerability of TNX-801: Tonix Pharmaceuticals announced the publication of a paper on the tolerability of TNX-801, a vaccine candidate. Tonix Pharmaceuticals announces peer-reviewed publication in Msphere Journal: Tonix Pharmaceuticals announced a peer-reviewed publication in Msphere Journal, highlighting the tolerability of TNX-801 in immune-compromised animals. Tonix Pharmaceuticals Holding Corp reports results for the quarter ended September 30: Tonix Pharmaceuticals reported quarterly losses that beat analyst consensus estimates. These articles provide insights into the company's research, publications, and financial performance. For more detailed information, you can click on the provided links. Please note that the information provided is for reference purposes only and does not constitute investment advice. Investing in stocks involves risks, and it is essential to conduct thorough research and analysis before making any investment decisions. Let me know if there's anything else I can assist you with!","text":"Yes, there are some good news articles about Tonix Pharmaceuticals (TNXP). Here are a few of them: Tonix Pharmaceuticals presents data, analyses of TNX-102 SL effects: Tonix Pharmaceuticals presented data in a poster presentation at the ACR Convergence 2024 Annual Meeting, highlighting the effects of TNX-102 SL. Tonix Pharmaceuticals announces publication of study on tolerability of TNX-801: Tonix Pharmaceuticals announced the publication of a paper on the tolerability of TNX-801, a vaccine candidate. Tonix Pharmaceuticals announces peer-reviewed publication in Msphere Journal: Tonix Pharmaceuticals announced a peer-reviewed publication in Msphere Journal, highlighting the tolerability of TNX-801 in immune-compromised animals. Tonix Pharmaceuticals Holding Corp reports results for the quarter ended September 30: Tonix Pharmaceuticals reported quarterly losses that beat analyst consensus estimates. These articles provide insights into the company's research, publications, and financial performance. For more detailed information, you can click on the provided links. Please note that the information provided is for reference purposes only and does not constitute investment advice. Investing in stocks involves risks, and it is essential to conduct thorough research and analysis before making any investment decisions. Let me know if there's anything else I can assist you with!","html":"Yes, there are some good news articles about Tonix Pharmaceuticals (TNXP). Here are a few of them: Tonix Pharmaceuticals presents data, analyses of TNX-102 SL effects: Tonix Pharmaceuticals presented data in a poster presentation at the ACR Convergence 2024 Annual Meeting, highlighting the effects of TNX-102 SL. Tonix Pharmaceuticals announces publication of study on tolerability of TNX-801: Tonix Pharmaceuticals announced the publication of a paper on the tolerability of TNX-801, a vaccine candidate. Tonix Pharmaceuticals announces peer-reviewed publication in Msphere Journal: Tonix Pharmaceuticals announced a peer-reviewed publication in Msphere Journal, highlighting the tolerability of TNX-801 in immune-compromised animals. Tonix Pharmaceuticals Holding Corp reports results for the quarter ended September 30: Tonix Pharmaceuticals reported quarterly losses that beat analyst consensus estimates. These articles provide insights into the company's research, publications, and financial performance. For more detailed information, you can click on the provided links. Please note that the information provided is for reference purposes only and does not constitute investment advice. Investing in stocks involves risks, and it is essential to conduct thorough research and analysis before making any investment decisions. Let me know if there's anything else I can assist you with!"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":356054665122192,"gmtCreate":1727936884097,"gmtModify":1727936889703,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/FFIE\">$Faraday Future Intelligent Electric Inc.(FFIE)$</a> future EV","listText":"<a href=\"https://ttm.financial/S/FFIE\">$Faraday Future Intelligent Electric Inc.(FFIE)$</a> future EV","text":"$Faraday Future Intelligent Electric Inc.(FFIE)$ future EV","images":[{"img":"https://community-static.tradeup.com/news/a958516703aa336869ff4835e527318b"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/356054665122192","repostId":"2472653825","repostType":2,"repost":{"id":"2472653825","kind":"live","pubTimestamp":1727928780,"share":"https://ttm.financial/m/news/2472653825?lang=&edition=fundamental","pubTime":"2024-10-03 12:13","market":"us","language":"en","title":"Faraday Future Announces Executives’ Common Stock Purchases","url":"https://stock-news.laohu8.com/highlight/detail?id=2472653825","media":"THOMSON REUTERS","summary":"Faraday Future Announces Executives’ Common Stock Purchases","content":"<html><body><p>Faraday Future Announces Executives’ Common Stock Purchases</p></body></html>","source":"reuters_en_live","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Faraday Future Announces Executives’ Common Stock Purchases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFaraday Future Announces Executives’ Common Stock Purchases\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-03 12:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241003:nTUABGMSVR:1><strong>THOMSON REUTERS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Faraday Future Announces Executives’ Common Stock Purchases</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241003:nTUABGMSVR:1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4555":"新能源车","BK4099":"汽车制造商","FFIE":"Faraday Future","BK4547":"WSB热门概念"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241003:nTUABGMSVR:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2472653825","content_text":"Faraday Future Announces Executives’ Common Stock Purchases","news_type":1},"isVote":1,"tweetType":1,"viewCount":341,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}